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82 Abstract
The prevalence and assessment of neuroleptic-induced movement disorders (NIMDs) in 
a naturalistic schizophrenia population that uses conventional neuroleptics were studied. 
We recruited 99 chronic schizophrenic institutionalized adult patients from a state nursing 
home in central Estonia. The total prevalence of NIMDs according to the diagnostic criteria 
of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) was 
61.6%, and 22.2% had more than one NIMD.
We explored the reliability and validity of different instruments for measuring these 
disorders. First, we compared DSM-IV with the established observer rating scales of Barnes 
Akathisia Rating Scale (BARS), Simpson–Angus Scale (SAS) (for neuroleptic-induced par-
kinson ism, NIP) and Abnormal Involuntary Movement Scale (AIMS) (for tardive dyskinesia), 
all three of which have been used for diagnosing NIMD. We found a good overlap of cases 
for neuroleptic-induced akathisia (NIA) and tardive dyskinesia (TD) but somewhat poorer 
overlap for NIP, for which we suggest raising the commonly used threshold value of 0.3 
to 0.65.
Second, we compared the established observer rating scales with an objective motor 
measurement, namely controlled rest lower limb activity measured by actometry. Actom-
etry supported the validity of BARS and SAS, but it could not be used alone in this natural-
istic population with several co-existing NIMDs. It could not differentiate the disorders from 
each other. Quantitative actometry may be useful in measuring changes in NIA and NIP 
severity, in situations where the diagnosis has been made using another method.
Third, after the relative failure of quantitative actometry to show diagnostic power in 
a naturalistic population, we explored descriptive ways of analysing actometric data, and 
demonstrated diagnostic power pooled NIA and pseudoakathisia (PsA) in our population.
A subjective question concerning movement problems was able to discriminate NIA 
patients from all other subjects. Answers to this question were not selective for other 
NIMDs.
Chronic schizophrenia populations are common worldwide, NIMD affected two-thirds 
of our study population. Prevention, diagnosis and treatment of NIMDs warrant more at-
tention, especially in countries where typical antipsychotics are frequently used. Our study 
supported the validity and reliability of DSM-IV diagnostic criteria for NIMD in comparison 
with established rating scales and actometry. SAS can be used with minor modifi cations 
for screening purposes. Controlled rest lower limb actometry was not diagnostically spe-
cifi c in our naturalistic population with several co-morbid NIMDs, but it may be sensitive in 
measuring changes in NIMDs.
93 Introduction
Schizophrenia is life-time disease that causes considerable suffering and economic bur-
den to the individual and society, and necessitates long-term treatment, sometimes for 
decades (Murray & Lopez 1997, Csernansky & Schuchart 2002). The treatment of schizo-
phrenia is based mainly on antipsychotic medication and various psychosocial treatments 
(Csernansky & Schuchart 2002). Traditionally, an obstacle to compliance with antipsychotic 
treatment has been the adverse effects, with movement disorders being particularly prob-
lematic (Csernansky & Schuchart 2002). Neuroleptic-induced movement disorders (NIMDs) 
have been suggested to be caused by blockade of dopamine 2 (D2) receptors in the basal 
ganglia and to some extent in cortical structures (Cross et al. 1985). Nowadays, in most 
developed countries, atypical antipsychotics, which cause less blockade of D2 and also af-
fect serotonergic receptors, are being used, and as they induce less NIMDs (Liebermann 
et al. 2003), these disorders may have become less common. In some parts of the world, 
however, even conventional antipsychotics are not available (World Health Organization 
2005). The prevalence of NIMDs in non-developed economies has not been thoroughly 
studied by contemporary instruments.
NIMD has traditionally been assessed and diagnosed by clinical evaluation and by ob-
server rating scales. Some established observer rating scales include the Barnes Akathisia 
Rating Scale (BARS) for neuroleptic-induced akathisia (NIA) (Barnes 1989), the Simpson–
Angus Scale (SAS) for neuroleptic-induced parkinsonism (NIP) (Simpson & Angus 1970) 
and the Abnormal Involuntary Movement Scale (AIMS) for tardive dyskinesia (TD) (Guy 
1976). These established instruments have not so far been studied against the current 
diagnostic criteria of NIMD.
These scales provide only a rough assessment, and they have been suggested to be 
insensitive to change (Caligiuri et al. 1997, Dean et al. 2004). Motor instrumental measure-
ment, an objective way of quantifying movement, has been postulated be more sensitive 
to changes, and perhaps more sensitive to fi nd NIMD cases (Tuisku et al. 2000).
Actometry has been used in different NIMDs, as an objective measure of disordered 
movement, and is a promising tool for diagnosing and measuring the severity of NIA 
(Tuis ku et al. 1999). It has not however, been used in a naturalistic setting. Moreover, it has 
not been properly studied in NIP or TD. Descriptive actometry has rarely been investigated 
in patients with several NIMDs simultaneously.
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4 Review of the literature
4.1 Antipsychotic drug treatment
Antipsychotics are drugs that specifi cally alleviate psychotic symptoms (i.e. not just by 
calming or tranquilizing the patient) (Deniker 1960). The fi rst of these drugs, chlor promaz-
ine, started a new era in psychiatry in the last half of the twentieth century, as for the 
fi rst time psychotic symptoms could be managed by a drug, and many psychotic patients 
no longer required physical restraint or chronic hospitalization (Denham & Carrick 1961, 
Davis & Casper 1977). Different classes of antipsychotic drugs, categorized according to 
their structure or profi le of action on different neurotransmitters, exist. The blockage of 
dopamine receptors is a key feature common to all antipsychotics.
Antipsychotic drugs include dopamine receptor antagonists or typical (or conventional) 
antipsychotics (e.g. chlorpromazine, haloperidol), serotonin-dopamine antagonists or 
atypical antipsychotics (e.g. risperidone, clozapine) and dopamine partial agonists (e.g. 
aripiprazole) (Lieber mann 2004).
4.1.1 History of antipsychotic treatment
Before 1950, psychiatry treated schizophrenia with non-specifi c biological treatments such 
as insulin coma, electroconvulsive therapy, narco-analysis and psychosurgery; the drugs 
used were opioid derivatives, barbiturates and chlorals (Healy 1996, Caldwell 1978).
Henri Laborit, a surgeon from France, tried to fi nd a drug that acted centrally on the 
autonomous nerve system to prevent surgical shock and administered chlorpromazine in 
1951. He identifi ed the psychotropic properties of chlorpromazine, as his patients did not 
lose consciousness; instead they had a tendency to drift off and become “disinterested” in 
their surroundings (Caldwell 1978).
Jean Sigwald, from the Val-de-Grace Hospital in France, started treating a psychotic fe-
male patient with chlorpromazine on 28.12.1951 at doses of 25–50 mg, and the patient’s 
hallucinations lost their threatening character (Caldwell 1978).
Delay and Deniker prepared a series of reports on using chlorpromazine for psychotic 
patients beginning in March 1952 (Deniker 1960). They presented their results on the 
effective ness of chlorpromazine at a scientifi c meeting in May 1952. Usage of chlor promaz-
ine rapidly spread over the world (Caldwell 1978). Several drugs similar to chlor promaz ine 
were synthesized within the next few years (Caldwell 1978). In 1958 Paul Janssen syn-
thesized haloperidol, which had relatively selective D2 receptor actions and therefore better 
tolerability (Cunningham Owens 1999). The use of neuroleptics was associated with extra-
pyramidal side-effects so frequently that these were seen as markers of effi cacy (Haase 
1961). The introduction of clozapine, an antipsychotic with minimal motor adverse effects, 
in 1966 made this correlation questionable (Healy 1996).
Nevertheless, the clinical impact of introducing neuroleptics was dramatic, as for the 
fi rst time the number of patients in chronic mental hospitals began to drop, and more and 
more individuals became manageable as outpatients (Davis & Casper 1977).
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4.1.2 Mechanism of action
The dopamine hypothesis has been offered as an explanation for the mechanism of action 
of antipsychotics (Carlsson & Lindqvist 1963). The simplest formulation of the dopamine 
hypothesis posits that schizophrenia results from excessive dopaminergic activity that af-
fects two of the main dopamine pathways in the brain – the mesolimbic and mesocortical 
pathways – producing changes in brain activity. The theory evolved from two observations. 
First, the potency of dopamine receptor antagonist drugs to reduce psychotic symptoms is 
most closely correlated with the affi nity of these drugs to D2 receptors. The mechanism of 
therapeutic action for dopamine receptor antagonist drugs is hypothesized to be through 
D2 receptor antagonism, which prevents endogenous dopamine from activating the recep-
tors (Carlsson & Lindqvist 1963). Second, drugs that increase dopaminergic activity, notably 
amphetamine, are psychotomimetic (Lieberman 1987).
Serotonin-dopamine antagonists or second-generation antipsychotics are antagonists 
of D2 receptors but have a diverse range of binding activities at other receptor types (Melt-
zer et al 1989). Clozapine has variable affi nities for several neurotransmitter receptors, 
including high affi nity for serotonin 5-HT2A, 5-HT2C , 5-HT6 and 5-HT7, histamine H1, and 
muscarinic acetylcholine receptors, but moderate or low affi nity for various dopamine re-
ceptors (Meltzer et al. 1989, Tarsy et al. 2002). Atypical antipsychotics with a low EP ad-
verse effects risk, and clozapine in particular, have relatively low affi nity and occupation 
levels at D2 receptors and at least moderate affi nity for D4 receptors, which are present 
mainly in cortical and limbic regions, with especially low prevalence in the basal ganglia 
(Tarsy et al. 2002). The dopamine partial agonists have partial agonist activity at both D2 
and 5-HT1A receptors (Liebermann 2004).
An antipsychotic will occupy dopamine receptor sites within an hour of a patient receiv-
ing an adequate dose of the drug (Farde et al. 1992), but the full antipsychotic effect takes 
several weeks (Deniker 1960; Liebermann et al. 2003).
The precise mechanism of action of antipsychotics remains unclear.
4.1.3 Clinical effects
All typical neuroleptic agents have the ability to reduce positive psychotic symptoms after 
several weeks of treatment (Deniker 1960, Denham & Carrick 1961). Some atypical anti-
psychotics have been shown to alleviate a greater variety of symptoms, resulting in more 
complete treatment response (Davis et al. 2003). Withdrawal of neuroleptic agents causes 
a relapse of psychosis in patients with schizophrenia, at the rate of approximately 10% 
per month, so that 50% or more will have relapsed by 6 months after discontinuation of 
neuroleptic agents. Consequently, long-term treatment with antipsychotics is indicated in 
schizophrenia for at least 1–2 years after alleviation of symptoms (Davis & Casper 1977, 
Csernansky & Schuchart 2002).
4.1.4 Adverse effects
The most common adverse effects of typical antipsychotics are extrapyramidal effects, 
which are described in detail in section 4.3.
Other side-effects are due to antihistaminic (weight gain) or alpha adrenergic (cardio-
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vascular side-effects – hypotonia) blocking, and anticholinergic properties (tachycardia, 
dry mouth, blurred vision, constipation, exacerbation of narrow angle glaucoma, urinary 
retention) (Malhotra et al. 1993). Metabolic changes (increase of blood glucose, glyco-
sylated haemoglobin, cholesterol, triglycerides) are associated more strongly with atypical 
anti psychotics (Lieberman et al. 2003, 2005).
The most common adverse effects associated with clozapine are sedation and hyper-
salivation (Liebermann & Safferman 1992). Neuroleptics may decrease the seizure thresh-
old (Woolley & Smith 2001).
Dermatological effects include skin rashes, pigmentation and photosensitivity. The most 
signifi cant neuroendocrine effect of antipsychotics is hyperprolactinaemia (Malhotra et al. 
1993).
Possibly fatal side-effects include malignant neuroleptic syndrome (Nagamine et al. 
2005), aplastic anaemia (remoxipride) (Laidlaw et al. 1993, Philpott et al. 1993), and 
agranulo cytosis with clozapine (Alvir et al. 1993, Idänpään–Heikkilä et al. 1997).
4.1.5 Pharmacoepidemiology
Economic resources differ between countries, resulting in different prescribing patterns.
Developed and developing economies
In 1989–1997 psychiatrists and other physicians in the United States prescribed olanza-
pine or risperidone 40% of cases in which antipsychotics were prescribed. The amount of 
typical antipsychotics over time has not changed, but prescribing of atypicals had grown 
(Hermann et al. 2002). In 1997, novel antipsychotics were prescribed for almost half of all 
psychotic patients (47%) in the United States. Prescribing practices were reported to be 
infl uenced by both facility and patient characteristics (Owen et al. 2001).
The prescribing patterns are similar in Europe. In 1998 in Italy 55% of schizophrenia 
patients received typical antipsychotics (Magliano et al. 2004). Typical antipsychotics ac-
counted for 44% of all antipsychotic prescriptions in the United Kingdom in 2003 (National 
Health Service 2003). According to data from the Finnish National Agency for Medicines 
(2002, 2005), 61% of antipsychotic DDD/1000 people in 2001 and 39% in 2004 were 
typical antipsychotics.
Typical antipsychotics comprised 72% of all prescribed antipsychotics in six East Asian 
countries (China, Hong Kong, Japan, Korea, Singapore and Taiwan) in 2001 (Chong et al. 
2004).
These fi gures show that in the developed economies a transition to use of atypical 
antipsychotics has occurred, and today a majority of prescriptions for schizophrenia are 
atypicals. The data about developing countries is extremely scarce, but the majority of 
prescriptions are not atypical antipsychotics and in some parts of the world even typical 
antipsychotics are not available (World Health Organization 2005).
Transitional economies
According to data from the Bulgarian Drug Agency, 73% of antipsychotic DDD/1000 people 
in 2001 were typical antipsychotics (Bulgarian Drug Agency 2005). According to the Czech 
Republic State Institute for Drug Control, 67% of antipsychotic DDD/1000 people in 2001 
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and 57% in the year 2004 were typical antipsychotics (personal communication, 2005). 
According to the Latvian State Medicines Pricing and Reimbursement Agency (2005), 59% 
of antipsychotic DDD/1000 people in 2004 were typical antipsychotics.
Estonia
According to an Estonian study conducted in 2001–2002, 12.8% of schizophrenia patients 
received clozapine and 10.5% new atypicals (mainly risperidone); all the others received 
typical antipsychotics (Jaanson 2002). Data from the Estonian Health Insurance Fund (per-
sonal communication 2005) indicate that 68% of patients with the diagnosis F20–F29 
were prescribed typical antipsychotics (haloperidol, melperone, fl upenthixole, chlorpro-
tixen, zuclopenthixol) and 32% atypical antipsychotics (clozapine, olanzapine, quetiapine, 
amisulpiride, risperidone) in 2004. According to the Estonian State Agency of Medicines, 
80% of antipsychotic DDD/1000 people in 2004 were typical antipsychotics (Eesti Ravi-
miamet 2005).
Taken together, these data show that in transitional economies the majority of anti-
psychotic drug prescriptions are still for typical antipsychotics.
4.2 Movement disorders
Movement disorders are neurological motor disturbances characterized by abnormally in-
creased motor activity or impaired back posture or by abnormally decreased motor func-
tion, mobility or posture (Chouinard 2004).
4.2.1 Classification
Movement disorders due to basal ganglia diseases are classifi ed into different clusters by 
the International Classifi cation of Diseases, 10th revision (ICD-10): the majority are classi-
fi ed as neurological diseases but some are classifi ed as mental and behavioural disorders 
(tic disorders including Gilles de la Tourette syndrome), some as endocrinological diseases 
(Wilson’s disease) and some as cardiological diseases (rheumatic chorea) (World Health 
Organization 1992). The DSM-IV defi ne a classifi cation for drug-induced movement dis-
orders, which is presented in section 4.3.4.
The causes of movement disorders can be neurodegenerative, vascular, hereditary, in-
fective, metabolic or drug-induced (Chouinard 2004, Alarcon & Gimenez-Roldan 2005).
Movement disorders can be divided into hypo- and hyperkinetic disorders (Litvan et 
al. 1998). The major features of akinetic-rigid syndromes are bradykinesia (small, slow 
movements), rigidity and tremor, often summarized as “parkinsonism” (Rice & Thomp-
son 2001a). Hyperkinetic movements are characterized by involuntary movements and are 
classifi ed according to their different patterns into syndromes of chorea, ballism, tremor, 
dystonia, myoclonus and tics (Rice & Thompson 2001b).
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4.2.2 Epidemiology
Approximately 80% of akinetic-rigid syndromes are due to Parkinson’s disease (PD) (Rice & 
Thompson 2001a). The prevalence of PD in Estonia is 152 per 100 000 individuals (Taba & 
Asser 2002). Published data indicate a PD prevalence of 108–257 per 100 000 in Europe 
(Campenhausen et al. 2005). Studies stating a higher prevalence include the parkinsonism 
syndrome; Hobson et al. (2005) found the prevalence of PD to be 105 and of parkinsonism 
to be 122 per 100 000. The prevalence of PD increases with age, reaching over 300 per 
100 000 in the age group 60–69 years, over 400 per 100 000 in the age group 70–79 years 
and over 900 in the age group 80 years or older (Campenhausen et al. 2005). For another 
akinetic-rigid syndrome, progressive supranuclear palsy, the age-adjusted prevalence was 
5 per 100 000 in Great Britain (Nath et al. 2001) and 6 per 100 000 in Japan (Kawashima 
et al. 2004).
The prevalence of essential tremor is 4.0% in the age group over 40 years (Dogu et al. 
2003). For restless legs syndrome, the 12-month prevalence is reported to be 8.5% in a 
French adult population (Tison et al. 2005).
For Huntington’s disease, a hyperkinetic syndrome, the prevalence is reported to be 4–8 
per 100 000 individuals (Harper 1992).
The prevalence of spontaneous dyskinesias in non-psychiatric patients was 0.8% be-
tween the ages of 50 and 59 years, 6% between the ages of 60 and 69 years, and 7.8% 
between the ages of 70 and 79 years (Klawans & Barr 1982).
According to this data, the prevalence of movement disorders in the general population 
is moderately low.
4.2.3 Movement disorders associated with mental disorders
An increasing amount of neuropathology has been found underlying the psychiatric dis-
orders classifi ed in the DSM-IV (American Psychiatric Association 2000). At one end of 
the continuum, this classifi cation includes primarily neurological diseases of an identifi ed 
organic aetiology with clear neurological and neurocognitive symptoms. At the other end 
of the continuum are disorders considered to be primarily psychogenic or functional (Beier 
1997). Between the two extremes are a large number of neuropsychiatric disorders with 
some neurological signs and some evidence of organic neuropathology, but in which the 
pathophysiological mechanisms are far from clear.
Motor abnormalities have been studied in, for example, schizophrenia, autistic dis-
orders, and attention defi cit hyperactivity disorder, all of which are considered neuro-
developmental disorders (Weinberger 1995, Taylor 1999, American Psychiatric Association 
2000, Tanguay 2000).
Minor motor abnormalities, also known as “soft signs”, are commonly encountered in 
each of these neurodevelopmental disorders (Jones & Prior 1985, Aronowitz et al. 1994, 
Flashman et al. 1996). While the clinical signifi cance of neurological soft signs is uncertain, 
they are widely regarded as indicators of non-specifi c brain damage (Kennard 1960). Soft 
signs include involuntary movements and abnormalities in gait, balance, laterality, integra-
tive sensomotor functions and motor coordination (Krebs et al. 2000). The term soft sign 
has, however, been criticized for having blurred boundaries (Sanders & Keshavan 1998). 
By defi nition, soft signs are neurological abnormalities that are not readily localizable to a 
specifi c brain region, while “hard signs”, or “major neurological signs”, like refl ex asym-
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metry, provide some indication of the underlying brain systems or regions affected (Sanders 
& Keshavan 1998).
Both soft and hard signs of nearly all functional domains are increased in schizophrenia, 
the subdomains of motor coordination and involuntary movements being the most promi-
nent (Ismail et al. 1998). Soft signs were present in 23% of neuroleptic-naïve schizophrenia 
patients and in 46% of schizophrenia patients treated with neuroleptics but were absent in 
control group. However, neither AIMS nor SAS distinguished the neuroleptic-naïve group 
from the group treated with neuroleptics, which shows that the greater prevalence in the 
treated group was due to a medication effect (Gupta et al. 1995). At least mild parkinson-
ism (SAS mean score higher than 0.1) was found in 17%, spontaneous mild dyskinesia in 
1% and probable akathisia in 5% of neuroleptic-naïve patients (Chatterjee et al. 1995).
4.3 Extrapyramidal adverse effects of neuroleptics
Extrapyramidal adverse effects are the various movement disorders that arise from taking 
antipsychotic drugs.
Four different movement disorders, i.e. NIP, NIA, acute dystonia and TD, are the most 
prevalent (Jenner & Marsden 1982, Wirshing 2001, Sachdev 2005).
Extrapyramidal adverse effects are among the most important reasons for non-compli-
ance with antipsychotic treatment, as they result in subjective suffering (van Putten 1974). 
They cause lowering of patients’ everyday function level, and social stigma (Kane et al. 1992, 
Krausz et al. 1999). Despite the increasing amount of atypical anti psychotics available, the 
extrapyramidal symptoms are still relevant in the treatment of psychosis because:
1 Globally, many patients continue to use conventional antipsychotics;
2 Even atypical antipsychotics may cause extrapyramidal symptoms (Miller et al. 1998, 
Tarsy et al. 2002);
3 Clinicians have a poor ability to identify NIMDs, which vary between 10% and 59% 
(Weiden et al. 1987, Hansen et al. 1992).
4.3.1 History
Almost immediately after introduction of neuroleptic drugs, reports have been made of 
extrapyramidal syndromes; NIP and NIA were reported by Steck in 1954 (Marsden & Jenner 
1980), acute dystonic reactions by Delay and Deniker in 1957 (Deniker 1960) and TD which 
became recognized after months or years of treatment, by Sigwald in 1959 (Marsden & 
Jenner 1980).
The reported prevalence of parkinsonism, akathisia and dystonia has been steady for 
years (Ayd 1961, McCreadie et al. 1992, van Harten et al. 1996, Halliday et al. 2002). TD 
was not reported in the fi rst surveys (Deniker 1960, Ayd 1961), but Faurbye used the term 
tardive dyskinesia for the fi rst time and reported a prevalence of 26% in 1964 (Faurbye et 
al. 1964, Friedman 2004). The Nithsdale studies have shown a doubling of prevalence of 
TD from 1982 to 2002 (Halliday et al. 2002).
The understanding of neuroleptic-induced extrapyramidal symptoms has changed over 
the years. In the past, when all existing antipsychotics caused extrapyramidal syndromes, 
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extrapyramidal symptoms were considered a necessary step in achieving an adequate anti-
psychotic effect (Denham & Carrick 1961, Haase 1961). After introduction of clozapine 
and other second generation (atypical) antipsychotics, these symptoms were considered an 
adverse effect of treatment, having no relationship with clinical effi cacy (Healy 1996).
4.3.2 Aetiopathogenesis
Cortical motor areas, cerebellum, basal ganglia and related subcortical nuclei, control nor-
mal movement. The classic NIMDs are mediated primarily by the impact on D2 receptors 
located in the extrapyramidal system. Those agents with high D2 receptor affi nity are as-
sociated with a greater risk of developing acute and late-onset movement disorders (Agnoli 
et al. 1983).
Such disorders are subserved primarily by the basal ganglia (Cross et al. 1985), which 
modulate motor activity through complex mechanisms, ultimately balancing inhibitory and 
stimulating impulses through dopamine and other neurotransmitters such as serotonin 
(5-hydroxytryptamine [5-HT]), acetylcholine, -aminobutyric acid (GABA) and glutamate. In 
this context, the optimal range of D2 blockade in drug-naïve patients may be very narrow. 
Kapur et al. (2000) have shown that typical antipsychotic D2 receptor occupancy in the 
corpus striatum that is greater than 78% is associated with increased risk of extrapyramidal 
side-effects and levels of less than 65% with suboptimal effi cacy. An important fi nding is 
that these levels can be achieved in fi rst-episode patients with haloperidol doses as low as 
1–5 mg per day (Kapur et al. 2000).
Neuroleptic-induced parkinsonism (NIP) is an extrapyramidal syndrome which in asso-
ciation with antipsychotic treatment is suggested to be caused by blockage of more than 
80% of the dopamine receptors (D2) in the nigrostriatal pathway (basal ganglia) (Farde et 
al. 1992). TD is proposed to be caused by development of increased sensitivity to dopamine 
in the nigrostriatal system as a consequence of chronic blockade by antipsychotic drugs 
(Klawans & Rubovits 1972, Tarsy & Baldessarini 1973). Mesocortical D2 receptor blockade 
by antipsychotic drugs (Marsden 1980) and imbalance between the noradrenergic and the 
dopaminergic systems (Blaisdell 1994) have been suggested to cause neuroleptic-induced 
akathisia (NIA). The risk of developing extrapyramidal symptoms is smaller with atypical 
anti psychotics compared with traditional antipsychotics probably due to their relatively 
lower D2 receptor occupancy and commensurately higher 5-HT2 occupancy (Goldstein 
2000) and their limbic selectivity (Arnt & Skarsfeldt 1998).
4.3.3 Typology
NIMDs, or extrapyramidal adverse effects, can be classifi ed into acute and tardive syn-
dromes on the basis of the temporal relationship with neuroleptic use (Wirshing 2001), or 
on their characteristics (hyperkinetic or hypokinetic, sometimes referred to as positive or 
negative) (Sachdev 1995). Acute NIMDs include acute dystonia, parkinsonism, akathisia 
and neuroleptic malignant syndrome (Sachdev 1995, Wirshing 2001). Tardive syndromes 
are classifi ed by phenomenology (e.g. chorea, dystonia, tics) and can, unlike their acute 
counterparts, be irreversible (Wirshing 2001).
The predominant tardive syndrome is tardive dyskinesia, although several related syn-
dromes have been described (Sachdev 2005). TD is a syndrome consisting of abnormal 
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involuntary movements, usually of the choreoathetoid type, sometimes stereotyped, princi-
pally affecting the mouth and face, sometimes the limbs, and occasionally the trunk (Jeste 
& Wyatt 1982). For research and clinical purposes, Schooler and Kane (1982) suggested 
the following research criteria for diagnosing TD: (1) at least 3 months of cumulative expo-
sure to neuroleptic medication, (2) the absence of other conditions that might cause the 
abnormal involuntary movements, and (3) movements of mild severity (score of 2 on the 
AIMS) in at least two discrete body parts or movements of moderate severity (score of 3 or 
more) in one body area. If these criteria are fulfi lled, a diagnosis of probable TD is made.
Dystonias most frequently occur during the fi rst fi ve days of treatment, though even a 
single dose of medication can induce a reaction (Ayd 1961). Acute dystonic reaction is a 
common adverse event characterized by involuntary muscular spasms that produce brief 
or sustained abnormal postures. These include oculogyric crisis, tongue protrusion, trismus, 
torticollis, laryngeal-pharyngeal constriction or bizarre positions of the limbs and trunk 
(Ayd 1961).
NIP may present with the classic triad of tremor, rigidity and bradykinesia, although 
only one symptom is necessary to establish the diagnosis (APA, DSM-IV). The tremor may 
have different manifestations and is often apparent at rest. Rigidity is commonly observed 
as a cogwheeling movement during passive fl exion-extension of the elbow or wrists. Brady-
kinesia manifests as a decrease in spontaneous activity, a mask faces and a loss of accessory 
movements with a festinant gait (Deniker 1960). NIP is manifested mostly in upper limbs 
(Hassin-Baer et al. 2001). NIP is more symmetrical and involves gait and posture less com-
monly than PD (Hassin-Baer et al. 2001).
NIA is characterized by an unpleasant (distressing) inner restlessness, an urge to move 
and the presence of restless movements (Sachdev 1995, Cunningham Owens 1999). NIA 
typically presents with restless movements, a coarse tremor and myoclonic jerking of the 
feet (Braude et al. 1983, Barnes & Braude 1985) NIA has marked and often distressing sub-
jective component. Pseudoakathisia (PsA) has only motor component of disorder (Munetz 
& Cornes 1982, Barnes & Braude 1985, Havaki-Kontaxaki et al. 2000).
The principal features of neuroleptic malignant syndrome are hyperthermia, muscle 
rigid ity, alteration in consciousness and autonomic dysfunction. The syndrome is poten-
tially fatal (Sachdev 2005).
4.3.4 Current classification
Unlike the ICD-10, DSM-IV classifi es medication-induced movement disorders (APA DSM-IV) 
into seven categories as follows:
NIP – Parkinsonian tremor, muscular rigidity or akinesia developing within a few weeks 
of starting or raising the dose of a neuroleptic medication (or after reducing a medication 
used to treat extrapyramidal symptoms).
Neuroleptic malignant syndrome – severe muscle rigidity, elevated temperature and other 
related fi ndings (e.g. diaphoresis, dysphagia, incontinence, changes in level of consciousness 
ranging from confusion to coma, mutism, elevated or labile blood pressure, elevated cre-
atine phosphokinase) developing in association with the use of neuroleptic medication.
Neuroleptic-induced acute dystonia – Abnormal positioning or spasm of the muscles of 
the head, neck, limbs or trunk developing within a few days of starting or raising the dose 
of a neuroleptic medication (or after reducing a medication used to treat extrapyramidal 
symptoms).
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Neuroleptic-induced acute akathisia – subjective complaints of restlessness accompa-
nied by observed movements (e.g. fi dgety movements of the legs, rocking from foot to 
foot, pacing, inability to sit or stand still) developing within a few weeks of starting or 
raising the dose of a neuroleptic medication (or after reducing a medication used to treat 
extrapyramidal symptoms).
Neuroleptic-induced TD – involuntary choreiform, athetoid or rhythmic movements 
(lasting at least a few weeks) of the tongue, jaw or extremities developing in association 
with the use of neuroleptic medication for at least a few months (may be for a shorter 
period in elderly persons).
Medication-induced postural tremor – fi ne tremor occurring during attempts to main-
tain a posture developing in association with the use of medication (e.g. lithium, anti-
depressants, valproate).
Medication-induced movement disorder not otherwise specifi ed – this category is for 
medication-induced movement disorders that do not belong to any of the disorders listed 
above. Examples include (1) parkinsonism, acute akathisia, acute dystonia or dyskinetic 
movement associated with a medication other than a neuroleptic; (2) a presentation re-
sembling neuroleptic malignant syndrome that is associated with a medication other than 
a neuroleptic; and (3) tardive dystonia.
4.3.5 Epidemiology of NIMD
The reported point prevalence for any NIMD in schizophrenia patient populations is 29–
74% (Ayd 1961, McCreadie et al. 1992, van Harten et al. 1996, Muscettola et al. 1999, 
Modestin et al. 2000).
Van Harten and colleagues (1996) reported a prevalence in the higher end because 
they considered four NIMDs, including tardive dystonia (13%). The Nithsdale schizophrenia 
survey assessing three NIMDs (TD, NIP and NIA) found a point prevalence of 29% for TD, 
27% for NIP, 18% for NIA, and 56% of schizophrenia patients had one or more NIMDs 
(McCreadie et al. 1992). After 11 years in the same region, the point prevalence of prob-
able TD was 43%, of NIP 35% and NIA 15% for 136 patients (Halliday et al. 2002). Despite 
long-term use of clozapine in a Zurich hospital, 42% of inpatients suffered from at least 
one NIMD (Modestin et al. 2000).
Based on epidemiological data, NIMD seems to be a relevant problem in antipsychotic 
treatment, although the reported prevalence fi gures differ due to different study popula-
tions and defi nitions.
4.3.6 Neuroleptic-induced akathisia
NIA, one of the most distressing adverse effects of antipsychotic treatment (Halstead et al. 
1994), can decrease patient compliance, increase psychotic symptoms (van Putten 1974) 
and provoke aggression (Stubbs et al. 2000).
NIA patients tend to experience inner restlessness, and restless legs syndrome patients 
tend to experience leg paresthesias as an antecedent to motor restlessness (Walters et al. 
1991). Restless legs symptoms are worse in the evening, while NIA symptoms are evident 
in the day time (Walters et al. 1991). 
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Epidemiology
NIA may appear within the fi rst few hours of antipsychotic exposure, but usually it takes 
days to weeks (Ayd 1961, Braude et al 1983).
The reported prevalence range for NIA is 9–35%, but the usual estimates are around 
20% for patients receiving antipsychotic treatment (McCreadie et al. 1992, Halstead et al. 
1994, Sachdev 1995, Van Harten et al. 1996, Cunningham Owens 1999, Muscettola et 
al 1999, Halliday et al 2002). A lower prevalence of NIA, 9.3%, was reported in a chronic 
inpatient setting (van Harten et al. 1996). A survey of 1559 in- and outpatients found an 
NIA prevalence 32% (Muscettola et al. 1999).
Socio-demographic variables (age, race, sex) do not appear to be signifi cant risk fac-
tors for NIA (Braude et al. 1983, Sachdev & Kruk 1994, Sachdev 1995, Chong et al. 2003, 
Kim & Buyn 2003). Instead signifi cant risk factors are drug-related, including high-potency 
drugs (Ayd 1961), drug dose and rapid dosage escalation (Braude et al. 1983, Sachdev & 
Kruk 1994).
Treatment
NIA may occur less frequently if patients are adequately informed, carefully monitored and 
encouraged to report adverse effects.
The recommended interventions to treat NIA are dose reduction of antipsychotic medi-
cation or switching to the drugs less likely to produce extrapyramidal symptoms (Taylor 
et al. 2001). When the intervention is not effective or proves impossible, either an anti-
cholinergic drug or propranolol could be added to the treatment, but the former may be 
effective only in patients with comorbid drug-induced parkinsonian symptoms (Barnes & 
McPhillips 1999, Taylor et al. 2001). The evidence for a benefi t with central action beta 
blocker or anticholinergics is weak (Lima et al. 2004a, 2005b). Secondary options include 
benzodiazepines, cyproheptadine and clonidine (Taylor et al. 2001). Low-dose mianserine 
has also shown some effectiveness (Poyurovsky et al. 1999), and other serotonergic drugs 
may prove useful in the future (Poyurovsky & Weizman 2001).
Prognosis
Braude et al. (1983) found that improvement of NIA occurred in all ten patients whose neuro-
leptic dose was reduced. Some patients experience withdrawal akathisia, which emerges 
after drug dose reduction (Barnes & Braude 1985). With maintenance anti psychotic treat-
ment, akathisia can become a long-term problem (Barnes & Braude 1985). NIA can be 
uncovered by switching to atypical antipsychotics (Tuisku 2000).
4.3.7 Neuroleptic-induced parkinsonism
NIP can produce an inability to perform everyday tasks because of rigidity and disturbed 
movements, compromising the patient’s quality of life (Cunningham Owens 1999). Rigid-
ity and dullness of thinking, sometimes called mental parkinsonism, have been described 
by patients in association with NIP (Hellewell 2002). NIP differs from Parkinsonian disease 
by more bilateral involvement with relative symmetry, and by affecting upper limbs more 
often than lower limbs (Hassin-Baer et al. 2001). NIP tends to be associated with the triad 
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of bradykinesia, tremor and rigidity, while PD more often involves gait and posture (Hassin-
Baer et al. 2001).
Epidemiology
NIP may develop within a few days of drug treatment, with 50–75% of cases appearing by 
one month and 90% within three months (Ayd 1961).
The point prevalence range for NIP is 15%–36% (Ayd 1961, McCreadie et al. 1992, van 
Harten et al. 1996, Muscettola et al. 1999, Halliday et al. 2002). Ayd (1961) using clinical 
impression found the point prevalence of NIP in large (3775 patients) survey to be 15%. 
Modestin et al (2000) reported that point prevalence of NIP using UPDRS in in-patients 
using typicals and clozapine was 20%. Recent studies using rating scales have found the 
point prevalence in chronic in-patients to be 36% with UPDRS (Van Harten et al 1996) and 
29% using a modifi ed version of SAS (Muscettola et al 1999). The Nithsdale population 
survey of 136 schizophrenia patients found that NIP was present as often in those receiving 
atypicals as in those receiving standard oral antipsychotics (29% and 27%, respectively) 
using SAS (Halliday et al. 2002).
Risk factors include use of higher doses of antipsychotics, high-potency typical anti-
psychotics, age over 40 years (corresponding to the age of onset of idiopathic Parkinsonian 
disease) and a basal ganglia dysfunction (Marsden & Jenner 1980, Ayd 1961). There is an 
individual susceptibility to the development of NIP in response to a given dose of neuro-
leptics (Jenner & Marsden 1982).
Treatment
The treatment strategies for NIP are reducing the dose of the neuroleptic or switching to 
a low-potency conventional neuroleptic or an atypical antipsychotic (Jenner & Marsden 
1982, Holloman & Marder 1997, Wirshing 2001).
Anticholinergics have traditionally been used to treat parkinsonian symptoms, and they 
have been used prophylactically for many years (Jenner & Marsden 1982, Wirshing 2001). 
Anticholinergics should not, however, be given for more than three months, as longer pe-
riods are neither necessary nor effective (Jenner & Marsden 1982). Compared with other 
available drugs, biperiden has a slightly higher affi nity for the muscarinic receptors that 
predominate in the central nervous system (Wirshing 2001). This means that biperiden is 
associated with fewer peripheral effects, although it still has the potential to cause confu-
sion and memory disturbances (Wirshing 2001).
The dopaminergic agent amantadine has been shown in several clinical trials to be as 
effective as anticholinergics in treating NIP (Ananth et al. 1975). Advantages of amanta-
dine over anticholinergics are that it may be better tolerated and that it does not adversely 
affect memory (Jenner & Marsden 1982).
Prognosis
Many patients respond to a reduction in neuroleptic dosage or a switch to a lower potency 
drug (Jenner & Marsden 1982).
The majority of patients are free of extrapyramidal signs within a few weeks of discon-
tinuation of neuroleptic therapy, but in some cases signs may persist for weeks or months 
(Jenner & Marsden 1982).
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4.3.8 Neuroleptic-induced tardive dyskinesia
TD is among the most serious adverse effects of long-term neuroleptic use in terms of its 
frequency, persistence, treatment resistance and overall impact on the well-being of pa-
tients and their caregivers (Kane et al. 1992).
Epidemiology
TD appears after many months or even years of drug treatment (Jeste et al. 1995).
The prevalence range for TD is 18–46% (Jeste & Wyatt 1981, Mukherjee et al. 1982, 
Koshino et al. 1992, McCreadie et al. 1992, van Harten et al. 1996, Cunningham Owens 
1999, Muscettola et al. 1999). Its prevalence has doubled over the last 20 years (Halliday 
et al. 2002).
Ageing is the main risk factor for TD (Mukherjee et al. 1982, Barnes et al. 1983, Jeste 
& Caligiuri 1993, Morgenstern & Glazer 1993). Other risk factors include female gender, 
mood disorders, diabetes mellitus and early extrapyramidal side-effects (Chouinard et al. 
1986, Jeste & Caligiuri 1993, Sachdev 2004). High rates of TD have also been reported in 
neuroleptic-treated individuals with mental retardation (Wirshing 2001, Sachdev 2005).
Longitudinal follow-up studies suggest that the cumulative incidence of TD increases 
with duration of neuroleptic treatment, at a rate of about 3–5% per year for the fi rst sev-
eral years, reaching a plateau of 20–25%. However, new cases continue to occur many 
years after drug initiation (Chouinard et al. 1986, Sachdev 2005).
Treatment
The primary strategy in the management of TD is preventative (Sachdev 2005). No effec-
tive treatment is available, although several drugs have been tried based on preliminary 
understanding of its pathophysiology (Sachdev 2005).
The treatment of TD involves careful risk-benefi t analysis of the patient history of psy-
chosis versus the disability caused by the movement disorder (Jeste and Wyatt 1982, Mal-
hotra et al. 1993). Although neuroleptic cessation appears to be a fi rst-line recommenda-
tion, no randomized controlled trials have been conducted to support this (McGrath & 
Soares-Weiser 2000). A number of pharmacological interventions proposed, including the 
use of non-neuroleptic catecholaminergic drugs, benzodiazepines, GABA agonists, cal-
cium channel blockers and tocopherol (vitamin E), have subsequently been shown to be 
ineffective (Lyra da Silva et al. 2005, Umbrich & Soares 2003, Soares et al. 2001, Soares 
& McGrath 2001a, 2001b). No evidence has emerged to indicate that anticholinergic and 
cholinergic drugs relieve TD (Soares & McGrath 2000, Tammenmaa et al. 2004). Some-
times transition to clozapine may alleviate TD symptoms (Louza & Bassitt 2005), but at least 
one case of clozapine-induced TD has been reported (Ertugrul & Demir 2005). 
Prognosis
For most people, TD does not become progressively worse; if it does get worse, it gen-
erally tends to show a fl uctuating course with some spontaneous remissions (Sachdev 
2005). In a fi ve-year follow-up study by Bergen et al. (1989), at each examination only 
two-thirds of the subject pool was TD-positive. Of the patients, 24% showed a fl uctuating 
course, 45% were TD positive at most examinations and 31% in at least one examination. 
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Of these patients who were consistently TD-positive, 82% showed no overall signifi cant 
change in AIMS scores, 11% improved and 7% worsened (Bergen et al. 1989). Within 
5–10 years, about 50% of patients demonstrate a 50% reduction in symptoms (Smith & 
Baldessarini 1980). The outcome is more favourable in the young and in those for whom 
drug treatment can be stopped (Smith & Baldessarini 1980). Improvement can be expected 
to continue for many years after neuroleptics have been terminated. The prognosis of 
withdrawal-emergent dyskinesia is more favourable, with over 75% showing improvement 
(Kane et al. 1992).
Jeste & Wyatt (1982) reported that TD remits in one-third of patients after three months 
of drug discontinuation and in 60% of patients after fi ve years.
4.3.9 Pseudoakathisia
PsA is not classifi ed in DSM-IV (APA 2004). This disorder has rhythmical movements, like 
NIA, but no subjective feeling of restlessness or distress (Munetz & Cornes 1982, Barnes 
& Braude 1985, Havaki-Kontaxaki et al. 2000). The overall prevalence of PsA has been 
reported to be 12.9% (van Harten et al. 1996), 4.8% in inpatients (Havaki-Kontaxaki et 
al. 2000) and 5% in outpatients (McCreadie et al. 1992). Munetz & Cornes (1982) have 
proposed that PsA is a progression of NIA to TD or a subtype of TD.
4.4 Measurement of neuroleptic-induced movement disorders
Methods of assessing human motor activity include systematic direct observations, self-
report questionnaires, observer-based scales and instrumental measurement (Caligiuri 
1994, Dale et al. 2002). Measuring movements and motor activity is common in clinical 
neurophysiology, neurology and sleep medicine, but it has also been utilized in psychiatry, 
geriatrics, orthopaedics, traumatology, physiatrics, occupational medicine and sports medi-
cine (Tuisku 2002).
Adverse events can be monitored in several ways: awaiting spontaneous reports by the 
patient, inquiring generally about adverse events, systematic interview, using a checklist of 
symptoms, inquiring generally about health and inquiring specifi cally about target events 
(Schooler & Chengappa 2000).
In addition to the clinical evaluation, several specifi c rating scales have been developed 
to assess acute and late-developing extrapyramidal side-effects of antipsychotic medica-
tions (Schooler & Chengappa 2000). Measures (e.g. scales) are designed to improve the 
reliability and validity of patient assessment over what might be accomplished in a standard 
clinical interview (Blacker & Endicott 2000). To be useful, observer-based rating scales must 
be reliable (i.e. have internal consistency, interrater reliability and test-retest reliability) and 
valid (i.e. accurate in representing the true event) (Blacker & Endicott 2000).
All motor extrapyramidal symptoms can be measured by objective instruments. Par-
kinson ian symptoms have been studied more than the others, initially because of the 
clinical importance of primary Parkinson’s disease (Caligiuri 1994). The earliest objective 
measure for recording fi nger tremor to revolving drum appeared in the literature in 1889 
by Peterson (Caligiuri & Tripp 2004). The earliest documented study in which an electro-
mechanical transducer was used to record rigidity was reported in 1959 (Webster 1959).
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4.4.1 Observational measurement
Observer-based rating scales for NIMD evaluation are designed to evaluate several NIMDs 
simultaneously (combined rating scales) or particularly one NIMD (specifi c rating scales).
Combined rating scales
Some rating scales are aimed to cover several different movement disorders included in 
NIMD measurement. The earliest examples from the beginning of the 1970s with 31 and 
4 items (Kennedy et al. 1971, van Putten 1974) had no names and were not used widely 
(Cunning-Owens 1999). The Smith Scale (Bell & Smith 1978) with 15 items, for instance, has 
not been used, according to a Medline search, in later published studies. The most widely 
used scales, the Extrapyramidal Symptom Rating Scale (ESRS) (Chouinard et al. 1980) and 
the St. Hans Scale (Gerlach et al. 1993), with 26 and 21 items, respectively, are complex 
and diffi cult to use in day-to-day practice, but reportedly have good statistical properties 
(Cunningham-Owens 1999). Recently developed combined rating scales for NIMD are the 
Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) with 8 subscales and one total item 
(Inada et al. 2002, 2003; Kim et al. 2002) and the Schedule for the Assessment of Drug-
Induced Movement Disorders (SADIMoD) with 8 subscales (Loonen et al. 2000).
Among the combined rating scales, one self-report has been developed, the Liverpool 
University Neuroleptic Side-Effect Rating Scale (LUNSERS) with 51 items (Day et al. 1995), 
which has demonstrated reasonable convergent validity with established NIA and NIP scales 
(Barnes Akathisia Rating Scale and Simpson–Angus Scale) (Jung et al. 2005).
Combined scales have been reported to be impractical in clinical use because of their 
exhaustiveness and complexity, and their usefulness therefore limited to the research set-
ting (Cunningham Owens 1999). However, since signifi cant overlap exists between the 
different NIMDs, a combined approach may be more suitable than using specifi c rating 
scales for individual NIMDs.
Specific rating scales
Standardized rating scales have been developed for three NIMDs (NIA, NIP and TD), but 
not for acute dystonia, which can not be evaluated by such a formal assessment because 
of the wide spectrum of symptomatology, the rapid progression and the considerable dis-
ability, which does not allow cross-sectional evaluation or patient participation (Cunning-
ham Owens 1999).
Neuroleptic-induced akathisia
For evaluation of NIA, several scales has been used, e.g. Hillside Akathisia Scale (Fleisch-
hacker et al. 1989), Barnes Akathisia Rating Scale (BARS) (Barnes 1989) and Prince Henry 
Hospital Akathisia Rating Scale (Sachdev 1994), BARS being the most established. Sev-
eral epidemiological and medication studies have used BARS (McCreadie et al. 1992, van 
Harten et al. 1996, Halliday et al. 2002).
BARS is a four-item anchored scale (Barnes 1989). The fi rst three items assess objective 
and subjective characteristics of akathisia on a scale from 0 to 3. The fourth item, termed 
the global item, is measured on a scale from 0 to 5, with higher scores indicative of more 
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severe akathisia. Brief instructions are provided for raters regarding administration, but 
specifi c questions to be used in assessing subjective akathisia are not included (Barnes 
1989). 
The interrater reliability Cohen’s kappa values have been as high as 0.738 in objective 
items, 0.827 in subjective awareness items, 0.901 in subjective distress and 0.955 in global 
clinical assessment (Barnes 1989).
The scale has been widely used in recent phase III trials of new antipsychotics (Lieber-
mann et al. 2003). Because these medications are hypothesized to reduce akathisia in 
comparison with typical antipsychotics, the studies provide opportunities to assess the 
validity of BARS (Schooler & Chengappa 2000). First-episode psychosis patients receiving 
olanzapine showed a statistically signifi cant mean reduction of 0.4 and patients receiving 
haloperidol showed a statistically signifi cant mean increase of 0.3 in the BARS score com-
pared with baseline (Liebermann et al. 2003). An earlier study used BARS for screening 
purposes to fi nd NIA cases and actometry found difference in activity levels of NIA and 
non-NIA patients, which supports the validity of BARS (Poyurovski et al. 2000).
Neuroleptic-induced parkinsonism
The Unifi ed Parkinson’s Disease Rating Scale (UPDRS) was designed for assessment of treat-
ment effi cacy of idiopathic PD, but has also been applied for assessment of NIP (Fahn et 
al. 1987). Several scales have been used to evaluate NIP, e.g. Mindham Scale (Mindham 
et al. 1972), Scale for Targeting Abnormal Kinetic Effects (Wojcik et al. 1980) and Simp-
son–Angus Scale (SAS) (Simpson & Angus 1970), and modifi cations of the latter (Lehmann 
et al. 1970, Rifkin et al. 1978, Perenyi et al. 1984, Caligiuri et al. 1989).
SAS is most widely used in epidemiological and medication studies (McCreadie et al 
1992, Halliday et al 2002, van Harten et al 1996, Liebermann et al 2003).
SAS contains ten items for assessing parkinsonian and related extrapyramidal side-
effects, each scored from 0 to 4, with higher scores indicative of more severe symptoms 
(Simpson & Angus 1970). These original items are gait, arm dropping, shoulder shaking, 
elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor and 
salivation. The mean score is obtained by adding all of scores and dividing by 10.
The mean interrater correlation coeffi cient between two raters was 0.87, with a range 
between 0.71 and 0.96, except for the salivation item, where it was between 0.16 and 1.0 
(Simpson & Angus 1970). SAS has been criticized for its item choice (6 of 10 items concern 
rigidity) and the low mean interrater reliability coeffi cients for the gait, wrist rigidity, tremor 
and salivation items (Cunningham Owens 1999). The intraclass correlation coeffi cients 
(ICC) for wrist rigidity, tremor and salivation items were below 0.34 in a study conducted 
in elderly patients (Sweet et al. 1993).
SAS validity was obtained from a study involving two levels of haloperidol and placebo; 
the difference between the haloperidol group and the placebo group was statistically sig-
nifi cant (Simpson & Angus 1970). A mean score of 0.3 was cited as the upper limit for 
patients without NIP or related extrapyramidal symptoms.
The scale has been widely used in recent phase III trials of new antipsychotics (Lieber-
mann et al. 2003). Because these medications are hypothesized to have fewer extra-
pyramidal side-effects than typical antipsychotics, studies of these medications provide 
opportunities to assess the validity of SAS (Schooler & Chengappa 2000). First-episode 
patients receiving olanzapine showed a statistically signifi cant mean reduction of 1.2, and 
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patients receiving haloperidol showed a statistically signifi cant mean increase of 0.6 in SAS 
score compared with baseline (Liebermann et al. 2003).
Neuroleptic-induced tardive dyskinesia
Abnormal Involuntary Movement Scale (AIMS) (Guy 1976, Munetz & Benjamin 1988) 
and the Rockland (Simpson) Tardive Dyskinesia Rating Scale (Simpson et al 1979) have 
been mostly used for evaluation of TD. Dyskinesia Identifi cation System: Condensed User 
Scale (DISCUS) was designed for developmentally based learning disabilities populations 
(Sprague & Kalachnik 1991).
AIMS was designed to record in detail the occurrence of dyskinesias in patients receiv-
ing neuroleptic medication (Schooler & Chengappa 2000). AIMS is by far the most estab-
lished scale for rating TD (Schooler & Chengappa 2000). It has been used in several epi-
demio logical studies (McCreadie et al. 1992, van Harten et al. 1996, Halliday et al. 2002).
The AIMS is a 12-item anchored scale (Guy 1976). Items 1–7 assess specifi c involuntary 
movements of the orofacial region, the extremities and the trunk. Items 8–10 deal with 
global severity, as judged by the examiner, and the patients’ awareness of the movements 
and associated distress. Items 11 and 12 are yes–no items concerning problems with teeth 
and/or dentures because such problems can lead to a mistaken diagnosis of dyskinesia.
Each item is scored on a scale from 0 to 4, with higher scores indicative of more severe 
movements. The AIMS total score is a sum of items 1–7. Item 8 (severity of abnormal 
movements) can be used as an overall severity index. Specifi c instructions are provided for 
asking the patient certain questions and having him/her perform certain manoeuvres (Guy 
1976). Score assignment is addressed well in an article by Munetz and Benjamin (1988).
Smith et al. (1979) assessed test–retest reliability, which range was from 0.12 to 0.75. 
Interrater reliability (Pearson correlation coeffi cients) in the same study ranged from 0.66 
to 0.82 for individual body area items. The correlation for overall severity was 0.75 (Smith 
1979). An interrater reliability ICC of 0.91 for the seven body areas was found when rating 
ten elderly patients with AIMS (Sweet et al. 1993). Satisfactory levels of test–retest con-
sistency have been achieved for AIMS (Lane et al. 1985, Sweet et al. 1993). However, the 
interrater variability often exceeds intra-rater variability, this has been shown also for AIMS 
and SAS (Bergen et al. 1984, 1988, Tonelli et al. 2003).
In terms of content validity AIMS seems to cover the commonly observed clinical fea-
tures that accompany TD (i.e. facial, oral, buccal, lingual, jaw and extremity movements) 
and the less common truncal movements. It does not cover rare or more severe movements, 
e.g. pharyngeal and respiratory movements or tardive dystonias (Schooler & Chengap pa 
2000). Use of a threshold, such as the Schooler and Kane criteria (1982), permits construct 
validity to establish a probable diagnosis of TD associated with antipsychotics (Schooler & 
Chengappa 2000).
AIMS has been used to assess TD in trials of the newer antipsychotic drugs (Tollefson et 
al 1997). The ability of new medication to produce lower AIMS scores provides evidence 
of the validity of the scale (Schooler & Chengappa 2000). Tollefson and colleagues (1997) 
compared 707 patients treated with olanzapine for a median of 237 days with patients 
treated with haloperidol for a median of 203 days. Using the total of AIMS items 1–7 as 
their dependent variable, they found that scores were reduced by an average of 0.13 scale 
points in the olanzapine group and increased by an average of 0.36 scale points in the 
haloperidol group, a statistically signifi cant difference (F = 9.02, df = 1.898, p = 0.003).
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Validity and reliability of rating scales
Rating scales bring reliability to psychiatric research, and thus have become a major means 
of psychiatric measurement. Monitoring for extrapyramidal side-effects is probably the 
most thoroughly developed area of adverse event measurement in psychiatry (Schooler & 
Chengappa 2000). Nevertheless, there are still some problems associated with observer 
ratings, such as variable reliability, non-linearity and poor sensitivity, which have been sug-
gested to be overcome by instrumentation (Kane et al. 1992).
4.4.2 Instrumental measurement
Interest in using instrumental measurement in addition to clinical examination and ob-
server-based rating scales has a long traditions. Instrumental measurement has been re-
ported (1) to identify more EPS patients than observer-based ratings (Cortese et al. 2005), 
(2) to be more sensitive to subclinical motor changes, (3) to exhibit greater linearity with 
regard to severity (Lohr & Caligiuri 1992, Caligiuri et al. 1997, Dean et al. 2004), and 
(4) to need less training to achieve suffi cient interrater reliability and test–retest reliability 
(Cali giuri et al. 1997).
Multiple methods have been used to instrumentally measure NIMDs, including elec-
tromyography (EMG), accelerometers, force and position transducers, ultrasound devices, 
digital movement analyses and videotape analyses (Lohr & Caligiuri 1992, Tuisku 2002).
An overview of studies in the fi eld of instrumental measurement of NIMDs is presented 
in Table 1.
Methods of instrumental measurement
Human motor activity can be measured directly as gross and fi ne three-dimensional move-
ments by accelerometric methods and as electric activity of motor units by EMG and its ap-
plications. EMG electrodes measure electrical signals emitted during muscle contractions.
Surface electrodes can detect activity from large superfi cial muscles, but more invasive 
needle or wire electrodes are needed to discriminate activity from smaller deep muscles. 
The disturbing effect of EMG electrodes on normal moving of subjects was studied in 
neuro logical child patients (Young et al. 1989), and as expected, the surface electrodes 
caused fewer disturbances.
Angular joint movements can be measured by electro-goniometers (e.g. strain gauges), 
which record the relative orientation of two bases connected by an elastic beam (Legnani 
et al. 2000). Position transducers show displacement and produce signals that can be 
mathematically differentiated to yield velocity and acceleration (Lohr & Caligiuri 1992, Cali-
giuri et al. 1999).
Strain gauges are also components of a force transducers, which measures muscle 
rigidity (Caligiuri 1994), defi ned as the ratio of changing muscle force to changing muscle 
length. A force transducer is attached to the limb of the patient, and the external force 
applied by the examiner to displace the patient’s limb is transduced along with rotation 
(Caligiuri 1994). The basic technique in force transducers consists of having the patient 
exert pressure on a rigid beam instrumented with strain gauges. The patient is instructed 
to maintain a constant force under isometric conditions for a set time period (Caligiuri et 
al. 1991, Lohr & Caligiuri 1992).
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Other indirect methods of measuring motor activity are, for example, ultrasonographic 
movement counters (May et al. 1983, Hoff et al. 1999) digital video camera movement 
analysis (Nilsson et al. 1996), photodetectors (May et al. 1983, Hoff et al. 1999), posturog-
raphy (Bloem et al. 1998, Lanska 2001), pedometers (Dale et al. 2002) and static charge-
sensitive beds (SCSB), which record electric potential changes in the mattress of the bed 
induced by body movements (Alihanka & Vaahtoranta 1979, Kronholm et al. 1993).
In addition to measuring body movements and motor activity of the muscles, other di-
mensions of motor functions, such as central magnetic or electric potentials, corticospinal 
excitability and peripheral conduction velocity (Rossini & Mauguire 1990), are measured in 
neuropsychiatry.
Accelerometry
Actometry and actigraphy are used in the literature as synonyms for recording methods 
based on accelerometric sensors. Actometry (actigraphy), a direct instrumental method for 
measuring human motor activity both quantitatively and qualitatively, was developed from 
accelerometry. Accelerometric applications include both old mechanical and more modern 
Table 1 Studies using instrumental assessment of NIMD.
Accelerometry EMG Force transducers
NIA Braude et al. 1984
Gardos et al. 1992
Rapoport et al. 1994
Tuisku et al. 1999
Tuisku et al. 2000
Poyurovsky et al. 2000
Cunningham et al. 1996
in polysomnography:
Lipinski et al. 1991
Walters et al.1991
Nishimatsu et al. 1997
NIP Collins et al. 1979
Rapoport et al. 1998
Caligiuri & Tripp 2004
Bathien et al. 1984
Rondot & Bathien 1986
May et al. 1983
May et al. 1983
Bartzokis et al. 1989
Wirshing et al 1989
Kern et al. 1991
Caligiuri et al. 1991
Caligiuri 1994
Caligiuri et al. 1999
Dean et al. 2004
Cortese et al. 2005
TD Denney & Casey 1975
Alpert et al. 1976
Chien et al. 1977
Fann et al. 1977
Stafford & Fann 1977
Nishikawa et al. 1986
Tryon & Pologe 1987
Sprague et al. 1993
Adler et al. 1999
Jus et al. 1973
Crayton et al. 1977
Bathien et al. 1984
Rondot & Bathien 1986
Nishikawa et al. 1986
May et al. 1983
Yasufuku-Takano et al. 1995
El-Mallakh et al. 2001
May et al. 1983
Bartzokis et al. 1987
Vrtunski et al. 1989
Vrtunski et al. 1994
Wirshing et al. 1989
Wirshing et al. 1991
Caligiuri et al. 1991
Caligiuri et al. 1997
Jeste et al.1995
Adler et al. 1999
Dean et al.2004
Cortese et al. 2005
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piezoelectric, computerized detectors, and they all react to acceleration signals produced 
by body movements. Accelerometers are small computerized movement detectors weigh-
ing only a few grams; they do not signifi cantly obstruct movement, nor do they impose a 
signifi cant inertial load (Lohr & Caligiuri 1992, Tuisku et al. 1999, Caligiuri & Tripp 2004). 
The modulation, integration and recording of the signal are varied, as is the output of 
the data, in different types of accelerometric methods and their commercial applications. In 
activity monitors (accelerometers), the three principal modes of data collection are known 
as “time above threshold”, “zero-crossing” and “digital integration”. In the fi rst mode, 
the monitor tracks the length of time that elapses from the point when acceleration ex-
ceeds a threshold value until it falls below the threshold. In the second mode, the monitor 
detects the number of times that acceleration crosses the zero point within a certain time 
period. In digital integration, the amount of acceleration is recorded and sampled at a high 
rate, and these values are used to calculate the average activity level within a time window 
(Gorny & Allen 1999, Spiro & Spiro 2001). All accelerometric monitors measure locomotor 
activity quantitatively, and some also allow qualitative motion analysis. The smaller the time 
window, the higher the time resolution of the movement (Tuisku 2002).
An increasing amount of data from accelerometric studies in psychiatry has been col-
lected, and activity monitoring has been suggested to be a valuable research tool for clin-
icians in diagnosis and prediction of treatment response (Teicher 1995). The customary use 
of accelerometric activity monitoring is diurnal recording with a relatively long sampling 
window ranging between several minutes and one hour. In diurnal activity monitoring, the 
monitors typically are attached to the non-dominant wrist in a wristwatch manner.
However, movement disorders such as NIA manifest predominantly in the lower limbs. 
Gardos et al. (1992) have created an accelerometric method for quantifying lower limb 
activity in this disorder. Rapoport et al. (1998) reported that all 14 NIP patients had tremor 
in upper limbs and only three had tremor in lower limbs.
Actigraphy has proved to be useful as a sensitive, non-invasive tool for measuring the 
effect of antipsychotics on spontaneous motor activity (Kiang et al. 2003).
Instrumental assessment of NIA
NIA has been studied mostly by accelerometry (actometry, accelerometric applications) 
(Braude et al. 1984, Gardos et al. 1992, Rapoport et al. 1994, Tuisku et al. 1999, Poyu-
rovsky et al. 2000, Tuisku et al. 2000) and by EMG (Cunningham et al. 1996), the latter 
being used mostly in polysomnographic studies (Lipinski et al. 1991, Walters et al. 1991, 
Nishimatsu et al. 1997).
Overall motor activity of eight NIA patients over a 24-hour period was measured by 
actometric monitor strapped to the non-dominant ankle, and NIA was found to have no 
relation ship with nocturnal activity and did not shorten the sleep period (Gardos et al. 
1992). Diurnal motor activity analysis of wrist-worn accelerometer data of 16 NIA patients 
and 16 non-NIA patients revealed that NIA patients had a higher level of motor activity 
during two day-time intervals. This could be the result of a morning dose of neuroleptics. 
A comparable increase at night was not evident because patients were asleep (Poyurovsky 
et al. 2000). Quantifi ed movement activity measured by accelerometers on ankles and 
waist in standardized rest-activity (30 minutes) discriminated 10 pure NIA patients from 
themselves in remission and from 10 healthy controls with no overlap. Only activity of 
the non-dominant ankle (left ankle) was used for statistical comparison, since no signifi -
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cant differences in laterality were found (Tuisku et al. 1999). This method was able to re-
veal akathisia in a patient who had mostly subjective complaints and hypokinesia-masked 
akathisia (Tuisku et al. 2000).
The toe tremor was more informative than the fi nger tremor in distinguishing six akathi-
sia patients from controls by actometry. Characteristic of NIA were low-frequency (less than 
4 Hz) rhythmic toe movements (Braude et al. 1984).
The movement pattern of NIA has been studied by accelerometric methods, with a 
monitor being placed over the body segment with the involuntary movement (mostly a 
leg). The qualitative analysis of actometric movement patterns (Tuisku et al. 1999, Rapo-
port et al. 1994) revealed characteristic patterns for NIA and PsA. In such a study 16 NIA 
patients manifested involuntary, intermittent, low frequency (less than 4 Hz) and rhythmic 
motor activity (Rapoport et al. 1994).
The movement patterns reported by accelerometric studies for NIA are consistent with 
those reported by EMG-derived from polysomnographic studies (Lipinski et al. 1991, Wal-
ters et al. 1991): relatively irregular but rhythmic bursts of lower limb activity of 0.5–3 Hz. 
An EMG study used a marker for akathisia that was 10 s in duration and less than 4 Hz in 
the anterior tibialis tracings to evaluate 26 subjects (16 NIA patients) (Cunningham et al. 
1996).
Instrumental assessment of NIP
NIP has been studied by EMG (May et al. 1983, Bathien et al. 1984, Rondot & Bathien 
1987) and by force transducers (May et al. 1983, Bartzokis et al. 1989, Wirshing et al. 
1989, Kern et al. 1991, Caligiuri et al. 1991, 1994, 1999, Dean et al. 2004, Cortese et al. 
2005). In addition NIP tremor has been investigated by accelerometry (Collins et al. 1979, 
Rapoport et al. 1998, Caligiuri & Tripp 2004).
NIP tremor occurred in the range of 5–7 Hz when recorded by EMG in a pair of an tagon-
ist muscles in studies with 8 and 12 NIP patients and was distinguishable from activity of 
TD (Bathien et al. 1984, Rondot & Bathien 1987).
Force and rotation transducers were useful in identifying asymmetries, measuring NIP 
hand tremor in the range of 4–6 Hz and rigidity in 21 patients with co-existing TD (Caligiuri 
et al. 1991).
Rigidity, bradykinesia and tremor were also assessed with wrist force and displacement 
transducer in a follow-up study with 56 older patients receiving a mean dose of 43 mg of 
chlorpromazine-equivalent antipsychotics, and a signifi cant increase in parkinsonism was 
found (Caligiuri et al. 1999).
Accelerometry revealed that the overall NIP tremor score by SAS and fi nger tremor 
frequencies were negatively and signifi cantly associated in 19 patients (Collins et al. 1979). 
PD, essential tremor and NIP tremor mean frequencies were similar for the resting tremor 
6.0 Hz (SD 1.13). Tremor power (which was calculated by summing the acceleration ampli-
tudes) had more variability, and the proportion of time that the hand movement met the 
criteria of tremor was 57% in NIP (Caligiuri & Tripp 2004).
Accelerometric recordings from 14 patients in frequencies between 4 and 7 Hz were 
helpful in differentiating neuroleptic-induced tremor from other NIMDs and psychogenic 
tremor, but their overall potential to distinguish neuroleptic-induced tremor from some 
other types of organic tremor was more limited (Rapoport et al. 1998).
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Instrumental assessment of TD
TD has been studied instrumentally by EMG (Jus et al. 1973, Crayton et al. 1977, May et 
al. 1983, Bathien et al. 1984, Nishikawa et al. 1986, Rondot & Bathien 1987, Yasufuku-
Takano et al 1995, El-Mallakh et al 2001), force transducers (May et al. 1983, Bartzokis 
et al. 1989, Vrtunski et al. 1989, 1994, Wirshing et al. 1989, 1991, Caligiuri et al. 1991, 
1997, Jeste et al. 1995, Adler et al. 1999, Dean et al. 2004, Cortese et al. 2005), ultra-
sound devices (Resek et al. 1981, Bartzokis et al. 1989, Kern et al. 1991, Wirshing et al. 
1991), digital image processing (Buchel et al. 1995, Nilsson et al. 1996, Stanilla et al. 1996) 
and accelerometers (Denney & Casey 1975, Alpert et al. 1976, Chien et al. 1977, Fann et 
al. 1977, Stafford & Fann 1977, Nishikawa et al. 1986, Tryon & Pologe 1987, Sprague et 
al. 1993, Adler et al. 1999).
The fi rst EMG study, with more than 20 TD patients, revealed several patterns and reg-
istered facial movements not visible in clinical observation (Jus et al. 1973).
Caligiuri group has done extensive TD research with force and position transducers. 
Force instability was used as an additional measurement to quantify hand and jaw dys-
kinesia in a study of TD risk factors (Jeste et al. 1995). Force transducers are highly reliable 
across multiple study sites – the overall ICC from 45 patients was 0.995 (Caligiuri et al. 
1997).
The accelerometer gave an abnormal movement frequency in one case of TD, 3.75 Hz, 
by spectral analysis measured between the fi ngers but not in the mouth (Denney & Casey 
1975). Fann et al. (1977) described a method to record the acceleration profi les in TD 
with triaxial accelerometers on the wrist, ankles and chin. Patients were measured in a 
laboratory while at rest and while performing alternating paced arm movements between 
predefi ned targets. Results using these methods were not, however, reported (Fann et al 
1977). Chien et al. (1977) described a signifi cant correlation between AIMS score and ac-
celerometry for 9 patients with oral TD who completed the study out of the original 15 
patients. An accelerometric study of 10 patients with TD and 8 controls revealed that TD 
patients had a lower peak for dyskinetic arm movements, and all patients were correctly 
classifi ed as to the presence or absence of TD (Tryon & Pologe 1987).
Bathien et al. (1984) described measuring by EMG sitting-position activity bursts of 
20 ms or more. Three consecutive 20-s epochs were analysed. The movement pattern 
was described as one of three types of irregular bursts below 3 Hz: type I 1–3 Hz, type II 
< 1 Hz, type III great variability. The mean frequency of neuroleptic-induced tremor was 
4.5 ± 1.1 Hz and the mean length 0.06 ± 0.01 s. TD was classifi ed into three types: types I 
and II were regular, with mean frequency of 1.6 ± 0.5 and 0.5 ± 0.2 Hz and a duration of 
0.27 ± 0.06 and 1.27 ± 0.35 s, respectively, type III had great variability, but was irregular, 
with a frequency 0–3 Hz (Bathien et al. 1984). Almost all TD patients (15/16) had abnormal 
activity in their limbs (Bathien et al. 1984, Rondot & Bathien 1987).
Reliability of instrumental measurement
Reliability, or consistency, between measurements made under uniform conditions is a 
necessary attribute for any assessment tool (Caligiuri et al. 1997).
Laboratory studies have demonstrated relatively high test–retest reliability using instru-
mental techniques. Isometric force procedures have yielded intra-patient reliability coeffi -
cients of 0.85 (Caligiuri & Lohr 1990). Procedures that count movements, such as position 
sensors (Trzepacz and Webb 1987) or ultrasonic techniques (Resek et al. 1981, Bartzokis 
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et al. 1989) are highly reliable, with test–retest correlation coeffi cients greater than 0.90. 
Gattaz & Buchel (1993) reported an intra-subject reliability coeffi cient of 0.84, using an 
automated digital video image processing system that evaluated oral movements. In a 
multicentre (n = 9) study using force transducers to evaluate TD, an ICC 0.995 was found 
for all patients across sites (Caligiuri et al. 1997).
Truncal accelerometry has shown high absolute test–retest repeatability in healthy sub-
jects – for walking tests ICC ranged from 0.79 to 0.94 for the three axes (Moe Nilsson 
1998).
Digital movement analysis of orofacial TD gave internal reliability (by test–retest) cor-
relation coeffi cients of 0.8–0.99, and the lowest coeffi cients particularly in Parkinsonian 
frequencies (3–6 Hz) were 0.8 and 0.84. In TD frequency bands, the lowest coeffi cient was 
0.94 (Nilsson et al. 1996).
Digital movement analysis validity was estimated by correlation with AIMS; Pearson r 
coeffi cients were between 0.54 and 0.73 (Nilsson et al. 1996).
The accelerometric recordings demonstrated in all cases of akathisia a constant and 
regular wave form, frequency (below 4 Hz) and amplitude. Actometric fi ndings were re-
producible, i.e. similar patterns appeared in several recordings of the same patient during 
the abnormal movements (Rapoport et al. 1994). Specifi city and sensitivity of instrumental 
measurement
An EMG study used a marker for akathisia that was 10 s duration and less than 4 Hz in 
the anterior tibialis tracings to evaluate 26 subjects (16 NIA patients); this method yielded 
a sensitivity of 69% and a specifi city 70% in detecting NIA (Cunningham et al. 1996).
Quantitative accelerometry had a trend towards positive correlation with the BARS 
global score (r = 0.56, p < 0.06), and NIA patients had a higher overall level of activity than 
patients without NIA (p < 0.01) (Poyurovsky et al. 2000). Actometric fi ndings had no over-
lap in differentiating selected NIA patients from non-NIA patients (Tuisku 1999).
A study of wrist rigidity in 29 patients revealed that an objective rigidity score, repre-
senting the degree to which motor activity increases muscular stiffness, correlated highly 
with clinical ratings of parkinsonian rigidity and demonstrated 89% specifi city and 82% 
sensitivity (Caligiuri 1994).
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5 Aims of the study
NIMD in a chronic naturalistic schizophrenia inpatient population in Estonia was exam-
ined. The prevalence of NIMD was estimated using different measuring methods, includ-
ing clinical rating scales and actometric measurement. Detailed aims of the study were as 
follows:
 I To assess the prevalence of NIMD in an Estonian naturalistic institutionalized schizo-
phrenia inpatient population by using various diagnostic criteria.
 II To evaluate the usefulness of a standardized actometric method (controlled rest activity 
measurement) and BARS in a clinical sample of unselected schizophrenia inpatients by 
comparing them with regard to case identifi cation and severity measurement of NIA.
 III To evaluate the internal consistency of SAS and improve convergence between DSM-IV 
and SAS-based NIP case fi nding, and to determine how the SAS measures objective 
motor symptoms verifi ed by actometry.
 IV To determine actometric patterns of NIMDs and PsA.
 V To evaluate the usefulness of a single self-rated question in the diagnosis of NIMDs and 
PsA.
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6 Subjects and Methods
6.1 Subjects
The subjects were 99 chronic schizophrenic institutionalized adult patients from a state 
nursing home in central Estonia. This typical Estonian nursing home had 354 inhabitants, 
172 of whom were diagnosed with schizophrenia or schizoaffective disorder. Reasons for 
institutionalization were mostly a low level of functioning and a poor support network, the 
latter of which is important in Estonia as the social welfare system is weak.
Inclusion criteria were a DSM-IV diagnosis of schizophrenia or schizoaffective disorder 
(American Psychiatric Association 2000), stable antipsychotic medication (for at least one 
month) and an age of 18–65 years. Diagnosis was made using a semi-structured interview 
according to DSM-IV criteria for schizophrenia or schizoaffective disorder by a psychiatrist 
(S.J.) and available medical records. Of the schizophrenia patients, 68 failed to meet inclu-
sion criteria: 63 due to old age and 5 due to not using antipsychotic medication. Exclusion 
criteria were severe somatic and neurological illness. One patient was excluded because of 
rheumatoid arthritis. In addition, there were 4 refusals.
After a complete description of the study to subjects, written informed consent was 
obtained. The Ethics Review Committee on Human Research of the University of Tartu ap-
proved the study protocol. Data were collected from 29.10.2001 to 27.03.2002.
6.2 Methods
6.2.1 Clinical evaluation
A psychiatrist (S.J.) assessed all subjects to identify any of three NIMDs (NIA, NIP or TD) in 
accordance with DSM-IV. In this study, NIMD is defi ned as occurrence of at least one of 
the three DSM-IV neuroleptic-induced syndromes. Furthermore pseudoakathisia was diag-
nosed using existing criteria (Barnes and Braude 1985, Rapoport et al. 1994). 
The temporal connection between a NIMD and PsA with neuroleptic medication was 
established retrospectively by interview and medical records.
The psychiatrist (S.J.) observed all patients’ for abnormal movements in the sitting and 
standing position.
The psychiatrist (S.J.) posed one subjective question to all patients concerning problems 
with movement: “Do you have troubles with movements, and if so, does it disturb you?” 
The answer was allocated to one of four categories:
a) No.
b) Yes, but it does not disturb me.
c) Yes, and it disturbs me.
d) Yes, and it is very diffi cult to cope with.
The psychiatrist (S.J.) evaluated postural tremor in patients’ outstretched hands. Rigidity 
was evaluated in upper limbs in the standing position. Rigidity in legs was evaluated with 
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patients sitting on a table. Rigidity in the neck was evaluated in a lying position on a couch. 
Gait and posture were evaluated when the patient walked in the corridor or in evaluation 
room.
6.2.2 Assessment scales
The Barnes Akathisia Rating Scale (BARS) (Barnes 1989) was used for assessment of clin-
ical akathisia (and pseudoakathisia), the Simpson–Angus Scale (SAS) (Simpson & Angus 
1970) for NIP, and the Abnormal Involuntary Movement Scale (AIMS) (Guy 1976) for TD to 
estimate prevalence and severity. For case fi nding, the threshold value for NIA was a BARS 
total score of 2 or more (scale range 0–5), and for NIP, SAS mean global score of 0.3 or 
more (scale range 0–4). TD cases were defi ned by AIMS according to the Schooler–Kane 
criteria, which require at least moderate dyskinetic movements in one body area or mild 
dyskinetic movements in two body areas (Schooler & Kane 1982).
6.2.3 Actometry
Ambulatory activity monitors of type PAM3 (IM-Systems, Baltimore, USA) were used to 
record subjects’ motor activity attached to both ankles. The mode of data collection in 
PAM3 is based on digital integration. These actometric monitors contain triaxial piezo-
electric accelerometer sensors that react to acceleration rates above 0.1 g. The recorded 
acceleration signal is sampled as an activity count at a rate of 40 Hz, and the values for 
each sample are used to calculate the average activity counts within a chosen time window, 
generally 0.1 s. The time window is suffi ciently small to allow analysis of movements within 
the range of EP movement disorders. With the 0.1 s time window, a 1 g acceleration equals 
approximately 106 activity counts. The movement index for a chosen time period is the 
sum of average activity counts for each time window included in this period (Tuisku 2002).
6.2.4 Controlled rest activity
Thirty minutes seems to be the maximum time that akathisia patients are able to maintain 
the sitting position (Rapoport et al. 1994) and it is long enough for motor symptoms to 
manifest (Barnes 1989). Moreover, it is the usual length of a clinical interview, effective 
in keeping the patient’s attention focused on the discussion. The patient is not instructed 
to sit still during the interview to allow spontaneous, natural movements. However, it is 
customary for a co-operative patient to remain seated in a medical interview even in the 
presence of an urge to stand up and walk (Tuisku 2002). Most often, patients who are able 
and willing to give informed consent are also suffi ciently co-operative to follow this type 
of procedure (Tuisku 2002).
Controlled rest activity is recorded in a standardized setting, in which the subject is ob-
served in a clinical assessment room. The solid, standard chair for subjects’ is equipped with 
a support for the back and hands, is located two metres from the interviewer, the clinician. 
The conversation with the subject is characterized by a low-stress, neutral atmosphere 
created by open questions and adhering to themes voluntarily discussed by the subject. 
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The interview opens with questions about the overall health record, including somatic, 
neurological and psychiatric history of symptoms, possible treatments, previous examina-
tions and routine health check-ups. Next, questions about the subject’s activity rhythms are 
posed concerning daily activity, sleeping and physical training habits. Each subject is asked 
about possible movement disorder or hyperactivity symptoms. The subject is also encour-
aged to talk about eating, drinking and smoking habits. Naturally, the subjects are aware 
of the actometric recording and the monitors attached to their bodies, but the idea of the 
interview is to focus their attention away from the monitors and from their own move-
ments to allow as naturalistic a setting as possible while maintaining a standardized and 
controlled situation (Tuisku 2002).
Controlled rest-activity of lower limbs (the average of right- and left-ankle activity) is 
the main outcome parameter (Studies II and III, and unpublished data). The non-dominant 
side is typically chosen for actometric recording (Nagels et al. 1996), as we did in Study 
IV, using the data of left ankle movements. Purposeful movements, which can mask 
more pathological movement patterns, are lateralized to the dominant side by defi nition 
(Springer & Deutch 1993). In actometry, both a qualitative and a small quantitative differ-
ence are present between the dominant and non-dominant upper limb activities (Nagels et 
al. 1996). However, data may be lost in unilateral analysis of motor activity, and defi nition 
of motor dominance can vary (Tuisku 2002).
Absolute movement indices are reported for controlled rest because it is a fi xed time 
period of 30 min (Tuisku 2002). Actometric movement index for 30 min of controlled rest 
activity was missing for one male patient due to non-cooperation. For this patient, we used 
the data for 20 min of controlled rest activity for descriptive analysis of movement patterns 
(Study IV).
6.2.5 Actometric evaluation of patterns of NIMD
Experienced raters of actometric data can evaluate raw actometric patterns quickly and 
intuitively (by the “picture” on the computer screen). We, however, wanted to develop a 
method that could be used by inexperienced raters. Five neuropsychiatrists developed con-
sensus-based rating instructions and a data-collection form. Data extraction was taught 
during two hours to two raters blind to the clinical diagnoses of subjects and patterns of 
movement disorders.
At the pilot stage of training, data for 8 subjects outside the study with different NIMD 
patterns as well as for 2 normal subjects were used. After achieving an appropriate level 
of interrater reliability (ICC = 0.44–1.0, mean 0.82), the two raters evaluated all subjects’ 
actometric activity recordings. After the pilot stage of raters’ training, the data extraction 
form was slightly modifi ed (we added a second and a third dominant frequency).
Raters assessed the raw data for the existence of activity periods, the number of activity 
periods (activity for at least 10 s), the existence of rhythmic activity, the three most domin-
ant frequencies and the highest acceleration peaks in activity periods (over 10 s). In the 
case of discrepant assessments, a consensus meeting, where raters reached a consensus 
for the frequencies of activity periods of 27 patients, was held after calculating interrater 
reliability.
Blindly extracted data by raters were evaluated to identify patterns for particular NIMDs, 
according to the DSM-IV diagnosis of NIMDs and the pseudoakathisia diagnosis (Barnes 
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and Braude 1985, Rapoport et al. 1994). We analysed the data for possible movement pat-
terns of NIMDs and PsA. Answers to the subjective question were correlated with move-
ment disorders diagnoses.
Raters achieved excellent interrater reliability in almost all parameters of movement 
patterns of actometric recordings, except in defi ning the minimal frequency of movement 
patterns. Interrater reliability coeffi cients are presented in Table 2.
6.2.6 Statistical analysis
In the fi rst study, we estimated the prevalence of NIMD using different approaches; a clin-
ical diagnosis according to DSM-IV and standardized rating scales for movement disorders 
(AIMS, BARS, SAS) were applied.
Student’s independent sample t-tests and chi-square tests were used to compare sub-
jects with and without NIMDs.
The correlation between the lower limb actometric activity index (mean activity of 
right and left ankles) and the BARS global score was analysed by Spearman correlation co-
effi cients in Study II. Differences between the NIA and the non-NIA patient median values 
in these variables were analysed by the Mann–Whitney two-tailed U-test. The perform-
ances of the two instruments in NIA case identifi cation were evaluated by receiver operat-
ing characteristics (ROC) analyses (Murphy et al 1987). Validity coeffi cients (specifi city and 
sensitivity) for different thresholds were calculated, and the cut-off points were defi ned by 
optimal trade-off between sensitivity and specifi city.
Cronbach’s alpha was calculated to evaluate the internal consistency of SAS in Study 
III. The correlations between lower limb activity (the mean of right- and left-ankle move-
ment indices) and individual item scores and mean SAS scores were analysed. Differences 
Table 2 Interrater reliability coeffi cients for 99 inpatients with schizophrenia: kappa for categori-
cal and intraclass correlation coeffi cients (ICC) for continuous measures.
 kappa
Presence of activity periods 0.905*
Presence of rhythmic activity 0.786*
 ICC (95% CI)
Number of activity periods 0.967 (0.951–0.978)*
Dominant frequency 0.739 (0.624–0.822)*
Second most prevalent frequency 0.787 (0.672–0.864)*
Third most prevalent frequency 0.789 (0.672–0.867)*
Minimal frequency 0.351 (0.149–0.525)#
Maximal frequency 0.831 (0.750–0.887)*
Highest value of acceleration peaks 0.841 (0.768–0.893)*
* p < 0.001   # p = 0.001
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between the NIP and non-NIP, as well as between the NIMD and the non-NIMD groups, 
in the SAS mean score and lower limb activity were examined. The performance of SAS 
mean score and individual item scores in case identifi cation was evaluated by ROC ana-
lyses against the DSM-IV NIP diagnosis. Validity coeffi cients (specifi city, sensitivity, positive 
and negative predictive value [PPV and NPV, respectively]) for different mean SAS score 
thresholds were calculated. To explore the discriminatory power of individual single SAS 
items’ we performed ROC analyses for each item separately. We also explored the effect 
on the validity coeffi cients of merging the six rigidity items of SAS into a single item to de-
emphasize the infl uence of rigidity on the mean SAS score. The Spearman test was used 
for correlation analysis and the Mann–Whitney two-tailed U-test for comparisons between 
two groups because of the non-normal distribution of the data.
The correlation between the lower limb actometric activity index (mean activity of right 
and left ankles) and the AIMS global score, was analysed by the Spearman correlation test 
(unpublished data). Performances of the two instruments in TD case identifi cation were 
evaluated by ROC analyses (Murphy et al. 1987). The area under the curve in ROC analyses 
range from 0.5 (no case-fi nding power) to 1.0 (optimal case-fi nding power). Validity co-
effi cients (specifi city and sensitivity) for different thresholds were calculated, and the cut-
off points were defi ned by optimal trade-off between sensitivity and specifi city.
The interrater reliability in Study IV was measured by kappa coeffi cients for categorical 
values and ICC (intra-class correlation coeffi cients) for continuous values to validate a new 
rating instrument lacking a “golden standard” (two-way ANOVA mixed model was used 
to calculate ICC in order to estimate the reliability of a single rating) (Fleiss 1981). One-way 
ANOVA was performed to determine whether a signifi cant ability to discriminate differ-
ent qualities of movement patterns exists. Differences between movement disorders (NIA, 
NIP, TD and PsA) and non-movement disorders groups in frequencies of activity periods 
were analysed by Mann–Whitney two-tailed U-test for continuous variables (frequency, 
number of periods). Chi-square test was used for dichotomous variables (presence of ac-
tivity periods, rhythmic activity). Fisher’s exact test for calculating signifi cance was used, if 
needed. The performances of qualities of movement patterns in case identifi cation were 
evaluated by ROC analyses.
Chi-square test was used for assessment of the self-rated question. The screening abil-
ity of the self-rated question for different NIMDs and PsA was evaluated by ROC analysis.
The software used in all analyses was SPSS version 12.0 (SPSS Inc. Chicago, IL, USA).
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7 Results
7.1 Participants
Of the 99 participants, 45 were male (45.5%) and 54 female (54.5%). Their mean age 
was 49.7 years (SD = 9.5). The mean documented length of continuous treatment in the 
hospital or nursing home was 13.6 years (SD = 9.0). Seventy-nine patients (79.8%) were 
receiving conventional antipsychotics and 20 (20.2%) clozapine (one was receiving cloza-
pine combined with sulpiride). Sixteen patients (16.2%) were receiving combinations of 
typical antipsychotics (either predominantly low-dose [n = 10] or predominantly high-dose 
[n = 6] neuroleptic regimens), and 63 (63.6%) were receiving monotherapy (haloperidol: 
n = 29; zuclopenthixol: n = 28; perphenazine, chlorpromazine, or thioridazine: n = 6). No 
new atypical antipsychotics were used. The mean daily chlorpromazine equivalent dose 
(Bazire 2000) was 328 mg (SD = 221). Seven patients (7.1%) received benzodiazepines, 
13 (13.1%) tricyclic antidepressants, 15 (15.2%) anticonvulsants and one (1.1%) lithium. 
Fourteen patients (14.2%) received the anticholinergic drug trihexyphenidyl. Seventy-one 
patients (71.7%) had paranoid, 7 (7.1%) disorganized, 9 (9.1%) catatonic, 2 (2.0%) re-
sidual, and 5 (5.1%) simple schizophrenia, and a further 5 (5.1%) had a schizoaffective 
disorder. Cognitive level of patients varied, with only one patient fulfi lling the criteria for 
dementia.
Sixty-four patients (64.7%) were smokers.
7.2 Prevalence of NIMD with various diagnostic criteria (Study I)
The point prevalence of any NIMD according to DSM-IV criteria was 61.6%; 31.3% had 
NIA, 23.2% had NIP, and 32.3% had TD (see Figure 1 for co-morbidity).
The prevalence of NIMDs in the patients receiving clozapine was signifi cantly lower 
than in those receiving conventional antipsychotics (35.0% versus 68.4%) (χ2 = 7.51, 
df = 1, p = 0.006). The mean age of those with a NIMD (51.5 years [SD = 8.5]) was sig-
nifi cantly higher than that of patients with no NIMD (46.9 years [SD = 10.4]) (t = –2.28, df 
= 97, p = 0.026). Among the NIMD categories, a signifi cant difference in mean age was 
found only in the NIP group (53.7 years [SD = 7.3] versus 48.5 years [SD = 9.8]; t = –2.77, 
df = 97, p = 0.008). Chi-square tests revealed no differences between patients with a 
NIMD and those without with respect to sex, smoking status and use of antidepressants, 
anti convulsants, benzodiazepines or anticholinergic drugs. Student’s independent sample 
t-tests also revealed no differences in length of institutionalization or antipsychotic dosage 
in chlorpromazine equivalents between patients with and those without a NIMD.
The prevalence of NIA according to global score on the Barnes scale was 27.3% (27 
patients), which was 92% consistent with the prevalence according to DSM-IV criteria (i.e., 
of 99 patients classifi ed as having or not having akathisia per the Barnes scale, the DSM-IV 
criteria similarly identifi ed 91; sensitivity = 93% [N = 25 of 27 similarly classifi ed as having 
akathisia], specifi city = 92% [N = 66 of 72 similarly classifi ed as not having akathisia]). The 
prevalence of NIP according to mean score on the SAS was 72.7% (72 patients), which 
was 50.5% consistent with the prevalence according to DSM-IV criteria (i.e., of 99 patients 
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classifi ed as having or not having parkinsonism per the SAS, the DSM-IV criteria similarly 
identifi ed 50; sensitivity = 32% [N = 23 of 72 similarly classifi ed as having parkinsonism], 
specifi city = 100% [N = 27 of 27 similarly classifi ed as not having parkinsonism]). The 
prevalence of TD according to the Schooler–Kane criteria for the AIMS was 31.3% (31 
patients), which was 99.0% consistent with the prevalence according to DSM-IV criteria 
(i.e., of 99 patients classifi ed as having or not having TD per the AIMS, the DSM-IV criteria 
similarly identifi ed 98; sensitivity = 100% [N = 31 of 31 similarly classifi ed as having TD], 
specifi city = 99% [N = 67 of 68 similarly classifi ed as not having TD]).
Figure 1 Prevalence of NIMD (NIA, NIP and TD) in a sample of 99 Estonian chronic schizophrenia 
patients treated with conventional antipsychotics or clozapine was 61.6%
    Without NIMD 
    38.4% 
          NIA 
          31.2% 
          10.1% 
   NIP              12.1% 
   23.2%  3.0% 
                6.1%  TD 
       32.3% 
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7.3 Evaluation of BARS and actometry (Study II)
The BARS global score did not correlate signifi cantly with the lower limb activity index 
in either the total population (r = 0.189, p = 0.063) or the NIA subgroup (r = 0.159, 
p = 0.393). After controlling for the effect of presence or absence of NIP and/or TD DSM-IV 
diagnoses (post-hoc analysis of co-variance), a signifi cant correlation between BARS global 
score and the lower limb movement index was found (r = 0.265, p = 0.009). The median 
BARS global score for NIA patients was signifi cantly higher than that of non-NIA patients 
(2 and 0, respectively, U = −8.20, p < 0.001). The median lower limb movement index for 
NIA patients was also signifi cantly higher than that of non-NIA patients (19870 and 10119, 
respectively, U = −2.82, p = 0.005).
In ROC analysis, AUC for BARS global score was 0.971 (95% CI = 0.945–0.998), and 
for lower limb activity index 0.683 (95% CI = 0.578–0.787).
The validity coeffi cients and the optimal cut-off points of the methods are presented 
in Table 3.
Table 3 Validity coeffi cients and optimal cut-off points (bold text) of the Barnes Akathisia Rating 
Scale (BARS) global score, and the lower limb activity index measured by actometry during a 30-
minute controlled rest in a clinical population of 98 chronic schizophrenia patients.
BARS  Cut-off < 1 < 2 < 3  
global
 
 
Sensitivity 1.00 0.81 0.48  score
 Specifi city 0.78 0.97 1  
 PPV 0.67 0.93 1  
 NPV 1 0.92 0.81  
Lower  Cut-off < 6000 < 8000 < 10 000 < 12 000 < 14 000
limb
  Sensitivity 0.90 0.87 0.81 0.77 0.74activity
 Specifi city 0.41 0.47 0.49 0.57 0.57index
 PPV 0.45 0.43 0.42 0.45 0.43
 NPV 0.87 0.89 0.84 0.85 0.81
7.4 Evaluation of SAS and actometry (Study III)
Only 10 of the 23 patients with NIP presented as pure NIP without co-morbidity of other 
motor disorders. Among patients with NIP, 10 had co-morbid NIA and 6 TD; three of the 
patients had all three. The SAS mean score correlated signifi cantly with age in our popula-
tion (r = 0.203, p = 0.044).
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7.4.1 Convergence of SAS and actometry to DSM-IV NIP diagnosis
The SAS mean score of DSM-IV NIP patients (1.24, SD = 0.44) was signifi cantly higher from 
that (0.56, SD = 0.33) of non-NIP patients (U = −6.90, p < 0.001). The mean scores of each 
single SAS item are presented in Table 4.
The mean scores of the “glabella tap” and “salivation” items for NIP patients were not 
signifi cantly higher than those for non-NIP patients. The SAS mean score for NIMD patients 
was signifi cantly higher from that for non-NIMD patients (U = −5.77, p < 0.001). The inter-
nal consistency of SAS measured by Cronbach’s alpha was 0.79. Tremor was rated at least 
“2” – tremor of hand or arm occurring spasmodically – for 54.5% of NIP patients.
Actometric data was missing for one male patient due to non-cooperation. The median 
lower limb movement index for NIP patients was not signifi cantly higher than that for non-
NIP patients (U = −0.46, p = 0.643). The median lower limb activity for NIMD patients was 
signifi cantly higher from that for non-NIMD patients (U = −2.66, p = 0.008).
7.4.2 Convergence of SAS to quantitative actometry
The SAS mean score did not correlate signifi cantly with actometric lower limb activity in 
either the whole population (r = 0.04, p = 0.717), the NIP group (r = −0.29, p = 0.192), 
the pure NIP subgroup (r = −0.21, p = 0.587) or the NIP subgroup with tremor (r = −0.16, 
p = 0.612).
Not even after a post-hoc analysis of co-variance in the whole population, where the ef-
fect of NIA (BARS global score) and TD (AIMS severity score) were controlled for, could any 
Table 4 Mean scores of Simpson–Angus Scale (SAS) items in the neuroleptic-induced par kinson-
ism (NIP) group and the non-NIP group.
 NIP group Non-NIP group
SAS item Mean (SD) Mean (SD) U p
Gait 1.04 (0.93) 0.38 (0.52) 501 < 0.001
Arm dropping 1.43 (0.73) 0.59 (0.62) 368 < 0.001
Shoulder shaking 1.09 (0.60) 0.33 (0.47) 326 < 0.001
Elbow rigidity 1.83 (0.58) 0.47 (0.55) 127 < 0.001
Wrist rigidity 0.91 (0.85) 0.16 (0.40) 437 < 0.001
Leg pendulousness 0.91 (0.85) 0.28 (0.45) 476 < 0.001
Head dropping 1.48 (0.85) 0.66 (0.83) 442 < 0.001
Glabella tap 1.09 (1.04) 0.86 (1.07) 755 0.286
Tremor 1.78 (1.13) 1.14 (0.92) 603 0.018
Salivation 0.83 (0.78) 0.71 (0.58) 818 0.603
Mean of SAS items 1.24 (0.44) 0.56 (0.33) 138 < 0.001
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signifi cant correlation between the SAS mean score and the lower limb movement index 
be found (r = 0.07, p = 0.494).
The tremor item of the SAS correlated signifi cantly with the lower limb movement in-
dex in the whole population (r = 0.25, p = 0.013) but not in the NIP population (r = 0.26, 
p = 0.248) or in the pure NIP subgroup (r = 0.51, p = 0.160).
No correlation was evidenced between the hypokinesia item of the SAS and the lower 
limb movement index in the whole population (r = −0.07, p = 0.513) in either the NIP 
population (r = −0.24, p = 0.290) or the pure NIP subgroup (r = −0.37, p = 0.797).
No correlation was found between the mean of rigidity items of the SAS and the lower 
limb movement index in the whole actometry sample (r = −0.12, p = 0.256) in either the 
NIP population (r = −0.37, p = 0.090) or the pure NIP subgroup (r = −0.30, p = 0.426).
7.4.3 NIP case finding by SAS
The ROC curve for diagnostic performance of the SAS mean score is presented in Figure 2. 
Area under the curve (AUC) for the SAS mean score was 0.92 (95% CI = 0.87–0.97). AUC 
of the ROC curve for the SAS elbow rigidity item was 0.93 (95% CI = 0.86–1.0). AUC for 
the other items was less than 0.82. The validity coeffi cients of the SAS mean score are 
presented in Table 5.
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Figure 2 Receiver Operating Characteristic (ROC) curve for the mean SAS mean score against the 
DSM-IV diagnosis of neuroleptic-induced parkinsonism (NIP).
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The ROC-curve for screening performance of the SAS mean with a single averaged 
rigidity item was clearly inferior to the original SAS mean curve with an AUC of 0.80 (95% 
CI = 0.70–0.89).
Performances of the individual SAS items for NIP case fi nding are shown in Table 6.
As the SAS elbow rigidity item had a case-fi nding power similar to the SAS mean score, 
Table 5 Validity coeffi cients of the Simpson–Angus Scale (SAS) mean score at different cut-off 
values. The optimal cut-off point range is presented in bold text.
SAS mean
cut-off 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 1.05 1.15
Sensitivity 1.0 1.0 1.0 1.0 1.0 0.96 0.87 0.78 0.70 0.52
Specifi city 0.17 0.36 0.45 0.49 0.62 0.74 0.86 0.86 0.89 0.93
Positive 
predictive
value 0.27 0.32 0.35 0.37 0.44 0.96 0.65 0.64 0.67 0.71
Negative 
predictive 
value 1.0 1.0 1.0 1.0 1.0 0.98 0.96 0.93 0.91 0.87
Table 6 Area under the ROC curve of Simpson–Angus Scale (SAS) parameters against the DSM-IV 
diagnosis of neuroleptic-induced parkinsonism.
SAS item Area under the ROC curve 95% Confi dence intervals
Gait 0.71 0.589–0.838
Arm dropping 0.79 0.690–0.889
Shoulder shaking 0.81 0.719–0.908
Elbow rigidity 0.93 0.855–1.000
Wrist rigidity 0.75 0.619–0.881
Leg pendulousness 0.73 0.603–0.853
Head dropping 0.75 0.636–0.858
Glabella tap 0.57 0.436–0.700
Tremor 0.66 0.530–0.781
Salivation 0.53 0.385–0.679
Mean of rigidity items 0.92 0.869–0.977
Mean of mean rigidity 
items and other SAS items 0.80 0.701–0.888
Mean of SAS items 0.92 0.869–0.973
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we calculated an optimal cut-off point for this item. A cut-off threshold of 1.5 with a sensi-
tivity of 0.83 and specifi city of 0.97, was superior to cut-off threshold of 0.5 with sensitivity 
of 0.96 and a specifi city of 0.55.
7.5 Evaluation of AIMS and quantitative actometry 
in measuring TD
Quantitative actometry failed to distinguish TD patients from non-TD patients.
The AIMS global score did not correlate signifi cantly with the lower limb movement 
index in either the total population (r = 0.13, p = 0.19) or the TD subgroup (r = 0.37, p = 0.03), 
or in TD subgroup without co-morbidity with (NIA, NIP and PsA) (r = 0.09, p = 0.81). AUC 
for the AIMS total score was 0.96 (95% CI = 0.92–1.01), and for the lower limb movement 
index 0.57 (95% CI = 0.45–0.69). Validity coeffi cients are presented in Table 7.
Table 7 Validity coeffi cients of the Abnormal Involuntary Movement Scale (AIMS) total score 
and the lower limb movement index at different cut-off values. The optimal cut-off point range 
is presented in bold text.
AIMS mean cut-off 0.5 1.5 2.5 3.5
Sensitivity 1.000 1.000 0.969 0.688
Specifi city 0.761 0.836 0.940 0.985
PPV 0.667 0.744 0.886 0.957
NPV 1.000 1.000 0.984 0.868
Lower limb activity 2000 4000 6000 8000
Sensitivity 0.938 0.875 0.750 0.688
Specifi city 0.075 0.269 0.343 0.373
PPV 0.326 0.364 0.353 0.344
NPV 0.714 0.818 0.742 0.714
7.6 Patterns of NIMD in actometry (Study IV)
Prevalence of PsA was 19.2%. The comorbidity with NIMD is shown on Figure 3.
Pooled NIMD and PsA patients had more activity periods in actometric recordings than 
patients without NIMD and PsA.
More than 95% of NIA and PsA patients showed rhythmic activity in actometric record-
ings. NIMD, particularly PsA and NIA, patients had higher frequencies in rhythmic activity 
than patients without NIMD and PsA. NIMD or PsA, except TD, patients had higher median 
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acceleration peaks in rhythmic activity recordings than non-movement disorder group pa-
tients. Results for each group are presented in Table 8.
The number of activity periods, presence of rhythmic activity, maximal frequency and 
highest values of acceleration peaks differentiated the subgroups of NIMDs and PsA. The 
other parameters of movement patterns showed no ability to discriminate between move-
ment disorder groups by one-way ANOVA.
The PsA group differed mostly from the non-movement disorder group with regard to 
median number of activity periods and frequencies. The ability of the presence of activ-
ity periods and rhythmic activity to discriminate between NIMD categories is presented in 
Table 9.
Data were limited to patients who showed rhythmic activity. The differences in the 
median number of activity periods and frequencies were greatest between the PsA and 
Figure 3 Comorbidity of PsA and NIMD in sample of 99 Estonian chronic schizophrenia inpatients 
treated with conventional antipsychotics or clozapine.
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non-NIMD groups. The results of actometric patterns of NIMD and non-movement disorder 
groups are presented in Table 10.
The medians of the highest acceleration peaks (biggest digital integration of accelera-
tion) in activity periods showed a trend to differ (U = 444, p = 0.053) between the NIP (216) 
and non-NIP (119) groups. No signifi cant differences were found between other groups.
The differences in medians of the highest acceleration peaks between selected particu-
lar NIMD and non-movement disorder groups are presented in Table 10. Median values 
of third most prevalent frequency and minimal frequency were not signifi cantly different 
between diagnostic categories.
To evaluate screening properties of actometry against DSM-IV and PsA diagnostic cri-
teria, we used ROC analysis. The area under the ROC curve (AUC) of the lower limb activity 
index was 0.80 for PsA. The AUC was 0.84 for actometric activity count of pooled NIA 
and PsA.
7.7 Usefulness of self-rated question in screening NIMDs
Answers to the subjective question on movement problems were different between the 
pooled NIMDs and PsA group and patients without NIMD or PsA (Pearson chi-square 
8.209, p = 0.004). The ROC curve for the subjective question screening performance in 
NIA is presented in Figure 4.
ROC analysis of the subjective question screening abilities showed an AUC value of 
0.67 for pooled NIMDs and PsA, 0.87 for NIA, 0.52 for NIP, 0.46 for TD and 0.25 for PsA.
Table 9 Presence of activity periods and rhythmical activity in differentiating neuroleptic-induced 
movement disorders for 99 in-patients with schizophrenia.
  Presence of Presence of
  activity periods  rhythmic activity
Non-movement disorders Pearson chi-square 5.547 2.726
vs. NIMD and PsA p 0.035 0.099
NIA vs. non-NIA Pearson chi-square 5.642 5.574
 p 0.016 0.019
NIP vs. non-NIP Pearson chi-square 0.113 4.505
 p 0.714 0.034
TD vs. non-TD Pearson chi-square 1.131 1.607
 p 0.495 0.254
PsA vs. non-PsA Pearson chi-square 0.814 2.061
 p 0.685 0.151
Pooled NIA and PsA  Pearson chi-square 8.491 11.027
vs. no akathisia p 0.004 0.001
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Table 10 Diagnostic group differences in actometric patterns of particular neuroleptic-induced 
movement disorders for 99 inpatients with schizophrenia. 
      Median
  Number     highest 
  of activity Dominant Second Maximal acceleration
  periods frequency frequency frequency peak
NIA median 13 0.58 0.60 1.15 177
non-movement 
disorder median 2 0.50 0.43 0.65 106
Mann-Whitney U 207 262 153 177 277
p < 0.001 0.084 0.017 0.001 0.040
NIP median 8 0.75 0.73 1.05 216
non-movement 
disorder median 2 0.50 0.43 0.65 106
Mann-Whitney U 282 127 58 143 145
p 0.140 0.040 0.009 0.106 0.023
TD median 9.75 0.55 0.55 0.95 127
non-movement 
disorder median 2 0.50 0.43 0.65 106
Mann-Whitney U 294 267 163 209 305
p 0.003 0.145 0.030 0.013 0.110
PsA median 16 0.8 0.8 1.15 144
non-movement 
disorder median 2 0.50 0.43 0.65 106
Mann-Whitney U 87 103 82 92 156
p < 0.001 0.004 0.011 0.002 0.042
NIA and PsA median 15.75 0.68 0.60 1.15 155
non-movement 
disorder median 2 0.50 0.43 0.65 106
Mann-Whitney U 641 364 235 269 433
p 0.003 0.011 0.006 < 0.001 0.017
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Figure 4 Receiver Operating Characteristic (ROC) curve for answers to subjective question and 
lower limb activity index against DSM-IV defi ned Neuroleptic-Induced Akathisia (NIA).
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8 Discussion
We studied the prevalence of NIMDs in a naturalistic, globally relevant, schizophrenia in-
patient sample that uses conventional neuroleptics and clozapine. We also explored the 
reliability and validity of different ways of measuring NIMDs. First, we compared the cur-
rent diagnostic criteria (DSM-IV) with the most established observer rating scales (BARS, 
SAS, AIMS), which are also used in diagnosing these disorders. We found a good overlap 
in NIA and TD diagnostics, but somewhat poorer overlap in NIP, for which we suggested 
raising the commonly used threshold value. Second, we compared the established observer 
rating scales to objective motor measurement, the controlled rest lower limb activity meas-
ured by actometry. Although quantitative actometry could not differentiate the disorders 
from each other, it did support the validity of BARS and NIP. However, it did not prove to 
be a suffi ciently valid instrument for use alone in a naturalistic population with co-morbid 
NIMDs. Still, actometry may be useful in measuring changes in NIA and NIP in situations 
where diagnoses have been made with another method. Third, after the failure of quanti-
tative actometry to show diagnostic power, we explored more qualitative ways of analysing 
actometric data and demonstrated some diagnostic power in the case of pooled NIA and 
PsA data in our population.
8.1 Prevalence of NIMD
We found that nearly two-thirds of patients suffered from a NIMD despite relatively low 
antipsychotic doses and the use of anticholinergics. The clinical practice in the study 
population was fi rst to lower the antipsychotic dose and then, if necessary, to add anti-
cholinergics.
To our knowledge, this is the fi rst prevalence study to use DSM-IV criteria for identifi ca-
tion of NIMDs and one of a few studies identifying the three NIMDs simultaneously. Since 
the mean antipsychotic dose in the study population was relatively low, we suggest that 
the prevalence of NIMDs is probably higher at the more commonly recommended anti-
psychotic doses.
We found a NIA DSM-IV prevalence of 31%. Previously reported NIA rates measured 
with BARS (Barnes 1989) are 9–11% in inpatients (van Harten et al. 1996, Modestin et al. 
2000) and 15–18% in communities (McCreadie et al. 1992, Halliday et al. 2002). In long-
term inpatients, 24% (Halstead et al. 1994) and in depot clinic outpatients 32%, are re-
ported to have akathisia (Barnes & Braude 1985), which agrees with our fi nding that long-
term patients have high prevalence of akathisia assessed with either DSM-IV or BARS.
We observed a NIP DSM-IV prevalence of 23%. Previously reported NIP prevalence rates 
measured by clinical impression (mild akinesia not included) are 15% (Ayd 1961) or with 
SAS 19% in large in- and outpatient surveys (Muscettola et al. 1999), and by UPDRS 20% 
in inpatients concomitantly using clozapine (Modestin et al. 2000). Higher rates (27–35%) 
are reported in surveys conducted in restricted areas using SAS (McCreadie at al. 1992, Hal-
liday et al. 2002) and in inpatients (36%) using UPDRS (Van Harten et al. 1996), which are 
much lower than our estimate using the SAS instrument (73%), but are consistent with our 
estimate using DSM-IV criteria (23%) in long-term patients also receiving clozapine. One 
reason for the high NIP prevalence measured by SAS in our study could be our long-term 
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patients had more rigidity, which was emphasized in SAS measurement. Muscettola et al. 
(1999) used slightly modifi ed SAS with less rigidity items.
We found a TD DSM-IV prevalence of 32%. Previously reported TD prevalence rates are 
29–32% in in- and outpatients (McCreadie et al. 1992, Mukherjee et al. 1982, Koshino 
et al. 1992) and 40–43% in long-term patients (Van Harten et al. 1996, Halliday et al. 
2002), which agree with our estimate of 32% in long-term patients with a mean age of 
50 years.
The prevalence rates of NIMDs defi ned by DSM-IV criteria and those obtained by rating 
scales were similar for NIA and TD but very different for parkinsonism. This could be due to 
the different focuses of DSM-IV and SAS criteria.
Despite the relatively low current antipsychotic dosage in our study, the prevalence 
of EPS was similar to that in previous studies. Thus the longer continuous treatment with 
antipsychotics, the potency of the antipsychotics and the older age of our patients made 
the prevalence here higher than in previous studies. Another important factor is that these 
chronic institutionalized patients had received much higher dosages of antipsychotics in 
the past.
8.2 Validity of BARS
BARS has been suggested to need objective validation by movement measurement (Barnes 
1989). Objective validation by actometry is possible only for the objective BARS item. In 
our study, the convergence between actometry and BARS (the correlation and the ability 
to discriminate between NIA and non-NIA groups) provides some objective support for the 
validity of BARS. This methodological study was the fi rst to compare BARS and actometric 
lower limb controlled rest activity in NIA in a large naturalistic population with different 
NIMDs. While both BARS and actometric lower limb controlled rest activity measures differ-
entiated the NIA group from the non-NIA group, BARS proved to be superior. Although an 
earlier report (Tuisku et al. 1999) suggests discriminant validity for quantitative actometry 
between pure NIA and non-NIA subjects, we were unable to distinguish NIA patients from 
the naturalistic sample. Tuisku et al. (1999) excluded NIP patients and used healthy people 
as controls. In our study, the confounding effect of other NIMDs with hyperactivity (PsA, 
parkinsonian tremor and TD) and possible subclinical forms of NIMD in patients prevented 
us from reaching a similar level of discriminant validity.
Actometric lower limb activity and the BARS global score correlated weakly but signifi -
cantly. The correlation became statistically signifi cant only after excluding or controlling for 
other NIMDs. The instruments measure somewhat different constructs; actometry records 
only movements, while BARS includes subjective experience in its score.
8.3 Validity of SAS
According to ROC analysis, SAS had good case-fi nding properties, converging with the 
DSM-IV NIP diagnosis. In our population, the commonly used cut-off threshold of SAS mean 
score 0.3 was inappropriate: according to our results, the optimal cut-off point should be 
between 0.65 and 0.95, depending on the emphasis in the trade-off between sensitivity 
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and specifi city. We therefore suggest that the cut-off value for screening of NIP should be 
0.65, whereby specifi city is doubled without losing any sensitivity. For diagnostic purposes 
a combination of high specifi city and high positive predictive value (PPV) is reached at cut-
off of 0.75 (Naarding et al. 2002).
The internal consistency of SAS was satisfactory, which suggests at least moderate 
reliability of the scale and is consistent with an earlier report (Loonen et al. 2000). We 
compared SAS with DSM-IV to assess the former’s discriminant validity and to evaluate its 
ability to detect NIP cases.
The comparison with objective movement assessment aimed to estimate the concur-
rent validity of SAS in NIMD diagnosing. As expected, the SAS had discriminant validity 
for a clinical diagnosis of NIP. The SAS mean score discriminated NIMD patients well from 
those without NIMD, and more specifi cally, also NIP patients from other patients. Actom-
etry discriminated NIMD patients from non-NIMD patients, but did not identify DSM-IV NIP 
patients. To investigate criticism about the overrepresentation of rigidity items (Cunning-
ham Owens 1999, Loonen et al. 2000), we averaged the six rigidity items to form one item. 
This procedure worsened the NIP case detection capacity of SAS. Using the single elbow 
rigidity item for case detection yielded the same (or slightly better) case detection capacity 
than the SAS mean score. This fi nding supports the use of elbow rigidity testing when as-
sessing parkinsonism in everyday practice, as the cut-off value of 0.5 has a good sensitivity 
and specifi city for DSM-IV NIP. Rating “0” means “normal” and “1” means “slight stiffness 
and resistance”.
In conclusion, SAS seems to be a reliable and valid instrument. It performs similarly to 
DSM-IV in NIP case detection. The optimal SAS mean score cut-off value in a naturalistic 
population of neuroleptic-treated schizophrenia patients is, however, higher than the com-
monly used 0.3. We suggest that the new cut-off value for screening of NIP could be 0.65, 
whereby specifi city is doubled without losing sensitivity. Pooling the SAS rigidity items did 
not improve the performance of the scale.
8.4 Lower limb controlled rest actometry in NIMD
We failed to detect subclinical movement disorders because we used DSM-IV (American 
Psychiatric Association 2000) and PsA (Rapoport et al. 1984, Barnes & Braude 1985) diag-
nostic criteria as the golden standards. Differences between Parkinsonian disease sub clinical 
resting tremor from controls in terms of amplitude fl uctuation, frequency dispersion, har-
monic index and proportional power in 4.4–6 Hz have, however, been reported by Beuter 
et al. (2005) using laser system measuring displacement.
8.4.1 Comparison of quantitative actometry and BARS
Both measures differentiated NIA from non-NIA group, but BARS proved to be superior 
to actometry in fi nding NIA cases. Although an earlier report has suggested discriminant 
validity for quantitative actometry between pure NIA and non-NIA subjects (Tuisku et al. 
1999), we were unable to accurately identify NIA patients in the naturalistic sample. This 
may be due to the confounding effect of other NIMDs (PsA, parkinsonian tremor and TD) 
manifesting with hyperactivity. With cut-off 12000 the sensitivity of actometry was 0.9 in 
53
fi nding akathisia cases. Asking about subjective symptoms (e.g., BARS awareness item) is 
still needed to rule out other NIMDs in a naturalistic population. Minor changes may be 
diffi cult to detect with BARS as compared with actometry. Quantitative lower limb activity 
index has proved to be a sensitive follow-up tool (Tuisku et al. 2002).
The convergence between actometry and BARS provides some objective support for 
the validity of BARS.
8.4.2 Comparison of quantitative actometry and SAS
We found that neither SAS mean score nor hypokinesia observed during the SAS gait item 
correlated with actometric lower limb activity. There are a few explanations for this: Firstly, 
actometry measures only the productive motor dimension of parkinsonian symptoms, while 
SAS also takes into account rigidity, gait, salivation and glabella tap, with a clear emphasis 
on rigidity. The lack of correlation with actometric fi ndings in the NIP subgroup indicates 
that tremor may not be the core feature of NIP. This is also supported by the small AUC for 
the SAS tremor item. Our fi nding is consistent with previous studies, which have reported 
tremor in 60% (Ayd 1961) and 44% (Hassin-Baer et al. 2001) of NIP patients. Secondly, we 
used lower limb actometry, although the clinical assessment by SAS and DSM-IV considers 
predominantly upper limbs. NIP may be more symptomatic in the upper limbs (Hassin-Baer 
et al. 2001), and upper limb disturbances may have infl uenced our SAS and DSM-IV assess-
ments more than lower limb disturbances. Our fi ndings indicate that lower limb actometry 
is not suitable for diagnosing NIP. Thirdly, diurnal naturalistic actometry may have more 
power than controlled rest activity window in detecting hypokinesia.
8.4.3 Descriptive actometry in different NIMDs
Actometry in NIA and PsA
Our fi ndings of actometric patterns of NIMDs and PsA agree with those of a previous 
accelero metric study (Rapoport et al. 1994), reporting no differences between clinical ob-
servations and accelerometric recordings of NIA and PsA.
Sachdev (1995a) has proposed that PsA is not a subtype of NIA. Differences in median 
values of actometric count for the PsA group and the non-movement disorder group in 
our study validates the diagnosis of PsA. These patients have higher frequency movements 
than other patients, but are unaware of them (according to answers to our subjective 
question). They have diffi culties in noticing their disturbance, which clearly distinguishes 
this disorder from NIA.
Actometry in NIP
The parkinsonian tremor shows rhythmic activity in accelerometric recordings, discriminat-
ing NIP patients from non-movement disorder patients. NIP patients had higher peaks of 
accelerations in activity periods than non-NIP patients. Comparing the NIP group with 
the non-movement disorder group made this fi nding more signifi cant. In our descriptive 
analysis, the frequencies of rhythmic activity in NIP were much lower (median below 1 Hz) 
than previously reported (above 4 Hz) (Bathien et al. 1984, Rapoport et al. 1998, Caligiuri 
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and Tripp 2004). One explanation may be that other NIMDs and PsA confound the results. 
Another possible explanation is that by measuring lower limb activity in the sitting posi-
tion we could not detect high-frequency NIP tremor. The latter is characteristic for upper 
limbs – all fourteen NIP patients had tremor in the upper limbs and three had tremor in 
accelero metric recordings of the lower limbs (Rapoport 1998), and another accelerometric 
study also measured tremor from the upper limbs (Caligiuri and Tripp 2004). There may 
have been a high-frequency tremor (close to 10 Hz) in our sample that we were not able to 
detect with our method due to limitations in the time window of our actometers.
Actometry in TD
Recording of movements of the ankle gave little information for detecting TD, despite the 
movement pattern of TD having more activity periods, more rhythmic activity, and slightly 
higher frequencies than non-movement disorder patterns. This is explained by TD affect-
ing other body segments than ankles, mostly the orofacial region and sometimes the legs. 
Another explanation could be that the non-movement disorder group included subclinical 
NIMD patients, who went undetected using DSM-IV criteria for NIMD. The second expla-
nation is supported by the following fi ndings: (1) up to 75% of non-movement disorder 
group patients by DSM-IV or PsA criteria showed rhythmic activity that might be related to 
movement disorders, seldom normal activity during rest; and (2) non-movement disorder 
patients had less activity periods in recordings, but when they had them, the frequencies 
were quite similar to those of NIMD (mostly TD) patients.
8.5 Subjective question
Almost all NIA patients have reported subjective complaints of movement problems in the 
lower limbs in previous studies (Braude et al. 1983, Sachdev & Kruk 1994). The subjective 
question on movement problems in our study was able to distinguish NIA patients from 
all other subjects. Answers to this question were highly selective for NIA cases, but not for 
other NIMDs or PsA.
8.6 Methodological issues
A strength of our study is the naturalistic non-selected inpatient sample. The sample was 
gathered from the largest nursing home in Estonia; approximately 13% of all institutional-
ized psychiatric patients in Estonia are treated there. The sample is representative of schizo-
phrenia and schizoaffective patients in the nursing home since 91% of all patients with 
these diagnoses aged 18–65 years participated. Medication of the sample represents typi-
cal medication available in state institutions for schizophrenia patients in Estonia (Jaanson 
2002). We can therefore generalize our results to other chronic schizophrenia inpatients, 
treated with mostly typical antipsychotics.
We achieved excellent interrater reliability in descriptive evaluation of actometric data 
with a relatively short training of inexperienced raters with no previous actometric rating 
skills (Study IV).
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We used 30-min controlled rest activity recorded with actometry because Tuisku et al. 
(1999) reported signifi cant differences in controlled rest activity of NIA patients compared 
with controls. A longer recording time (14.5 hours) did not show signifi cant differences 
between these groups (Tuisku et al. 1999) and would be impractical in our study design.
We used several assessment methods for NIMDs simultaneously, which allowed us to 
compare the diagnostic criteria of rating scales and an objective assessment method, ac-
tometry.
The main limitations of this study are connected to the nature of NIMD: (1) co-occur-
rence of spontaneous movement disorders, commonly detected in schizophrenia popula-
tions (Chatterjee et al. 1995), could not be excluded, and (2) the DSM-IV diagnoses of 
NIMDs in this study, as in clinical settings in general, are partially based on retrospective 
information.
The co-morbid movement disorders that exist in this real-life sample may have partially 
overlapping characteristics. The differentiating ability of actometry was not high for indi-
vidual NIMDs.
Another limitation of the study is that for practical reasons the clinical diagnosis of 
NIMD or PsA, the ratings for scales and the subjective question was all assessed by the 
same clinician, which could result in judgement bias. Furthermore, as there was only one 
rater for the scales, a cross-scale contamination might have occurred.
DSM-IV was used as the standard in this study; however, little data are available on 
the validity of the NIMD criteria of DSM-IV. A better golden standard would probably have 
been an expert-consensus diagnosis. Another limitation here was that subclinical move-
ment disorders went undetected since we used DSM-IV (American Psychiatric Association 
2000) and PsA (Rapoport et al. 1984, Barnes and Braude 1985) diagnostic criteria as a gold 
standard.
This study was limited to a few aspects of the utility/validity of SAS: internal consistency, 
convergence to DSM-IV NIP diagnosis and convergence to objectively measured motor 
activ ity. Many aspects of the scale’s reliability (e.g. test-retest and interrater reliability) and 
validity (e.g. construct) were not evaluated. With age, the prevalence of spontaneous 
NIMDs is known to rise. While our material did not allow a thorough examination of the 
issue, age did correlate with SAS mean score.
The limitation of actometric data collection was the recording of only ankle activity; 
recordings from the wrist and legs could give more information, especially in case of NIP, 
which is manifested more in the upper limbs (Hassin-Baer et al. 2001).
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9 Conclusions and future considerations
9.1 Conclusions
Chronic schizophrenia populations, similar to our study population, are common world-
wide. NIMD affected two-thirds of our study population. Prevention, diagnosis and treat-
ment of NIMDs warrant more attention, especially in countries, where typical antipsychotics 
are frequently used. Our study supported the validity and reliability of DSM-IV diagnostic 
criteria for NIMD in comparison with established rating scales and actometry. BARS and 
SAS are valid instruments in diagnosing NIA and NIP, respectively. However, commonly ap-
plied SAS threshold for diagnosing NIP should be raised from 0.3 to 0.65. Controlled rest 
lower limb actometry did not achieve suffi cient specifi city in our population with several 
co-morbid NIMDs and PsA, but it may be sensitive in measuring changes in NIMDs or PsA. 
The subjective question on movement disturbances was highly specifi c and cost-effective 
in detecting NIA, but not other NIMDs or PsA.
9.2 Clinical implications
Nearly two-thirds of institutionalized schizophrenia patients were shown to suffer from 
adverse effects of conventional antipsychotics. Since the costs of switching to atypical 
antipsychotics are too high for many countries, other ways of coping with NIMDs must be 
explored, such as lowering antipsychotic dosage and using clozapine or anticholinergics.
Our subjective question was specifi c for NIA cases, but not for other NIMDs or PsA, 
probably because of the subjective component of NIA. Posing such a subjective question is 
a cost-effective way of screening for NIA. Careful questioning of patients is useful method 
of diagnosing NIA in clinical setting. The use of elbow rigidity testing has good sensitivity 
and specifi city for DSM-IV NIP. Actometry does not offered any advantages in diagnosing 
TD in comparison with structured clinical observation using AIMS.
9.3 Implications for research
Actometric lower limb recording and analysis are moderately time-consuming but use-
ful for differentiating pooled NIA and PsA patients from other patients in a non-selected 
populations, but do not discriminating between these two subgroups. Exact recording of a 
patient’s present state is an advantage of actometry. Because our study was cross-sectional, 
we were unable to show changes in movement activity index or patterns after changes in 
risk factors (e.g. dosage, antipsychotic type and time course). Future research should con-
centrate on whether actometry is sensitive to change, especially in comparison with rating 
scales. The fi rst studies have been done already (Adler et al. 1999, Tuisku et al. 1999).
The epidemiology of NIMDs and PsA should be studied in a naturalistic schizo phrenia 
population using mostly atypical antipsychotics to estimate their prevalence and inci-
dence.
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